<!DOCTYPE html>

<html> 

<head> <!-- /main page header -->
  <meta charset="UTF-8">
   <meta name="format-detection" >
   <meta name="viewport" content="user-scalable=no, initial-scale=5, minimum-scale=1, maximum-scale=5">
   <title>BD-MIMS</title>
   <link rel="stylesheet" href="css/main.css">
   <link rel="stylesheet" href="css/themes/default/jquery.mobile-1.3.1.min.css">
   <script src="js/jquery.js"></script>
   <script src="js/jqm.js"></script>
   <script scr="js/cordova.js"type="text/javascript"></script>
   <script>
    function init() {
      document.addEventListener("deviceready", onDeviceReady, false);
    }

    function onDeviceReady() {
      alert('');
    }
  </script>
   
</head> <!-- /main page header -->


<body onload="init()"> 


<div data-role="page" id="" data-theme="a"> <!-- /first page -->


    <div data-role="header"> <!-- /this is header -->
      <h1> Drugs Acting on Nervous System</h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>

    </div> <!-- /this is header -->


<div data-role="content" data-theme="a">  <!-- /content div -->
  <ul data-role="listview" data-inset="true" data-theme="b">        
                   
    <li> DRUGS USED IN DIABETES
        <ul>
	       <li><a href="#Insulin">
	        Insulin & its preparations </a>
	       </li>
	       <li><a href="#Oral hypoglycaemic drugs">
	        Oral hypoglycaemic drugs</a>
	       </li>
	       <li><a href="#Combination preparations">
	        Combination preparations </a>
	       </li>	       	            
	    </ul>             
    </li>  
            

	<li><a href="#THYROID">THYROID & ANTITHYROID DRUGS </a></li>
	      	       	            
    <li> CORTICOSTEROID DRUGS/HORMONES
        <ul>
	       <li><a href="#BETAMETHASONE">BETAMETHASONE </a></li>
	       <li><a href="#DEXAMETHASONE">DEXAMETHASONE </a></li>
	       <li><a href="#HYDROCORTISONE">HYDROCORTISONE </a></li>
	       <li><a href="#PREDNISOLONE">PREDNISOLONE </a></li>
	       <li><a href="#METHYL PREDNISOLONE">METHYL PREDNISOLONE </a></li>
	       <li><a href="#METHYL SODIUM">METHYL PREDNISOLONE SODIUM </a></li>
	       <li><a href="#TRIAMCINOLONE">TRIAMCINOLONE </a></li>            
	    </ul>             
    </li> 

	 <li> SEX HORMONES
	     <ul>
		       <li><a href="#Female sex hormones">
		        Female sex hormones </a>
		       </li>
		       <li><a href="#Male sex hormones">
		        Male sex hormones</a>
		       </li>
		       <li><a href="#Anabolic steroids">
		        Anabolic steroids </a>
		       </li>	       	            
		    </ul>             
	 </li>         

	  <li> HYPOTHALAMIC & PITUITARY HORMONES & ANTI-OESTROGENS
	      <ul>
	 	       <li><a href="#Drugs for Sterility">
	 	        Drugs for Sterility </a>
	 	       </li>
	 	       <li><a href="#Drugs for Growth failure">
	 	        Drugs for Growth failure</a>
	 	       </li>
	 	       <li><a href="#Drugs for milk suppression">
	 	        Drugs for milk suppression </a>
	 	       </li>	
	 	       <li><a href="#Drugs for menopausal symptoms">
	 	        Drugs for menopausal symptoms: <br>
	 	        Hormone replacement therapy</a>
	 	       </li>
	 	       <li><a href="#Hormone prepns. for other uses">
	 	        Hormone prepns. for other uses </a>
	 	       </li>       	            
	 	    </ul>             
	  </li>         

	  <li><a href="#OTHER ENDOCRINE DRUGS">OTHER ENDOCRINE DRUGS </a></li>

 </ul> 
</div> <!-- content div -->

   <div data-role="footer"data-position="fixed"> <!-- /first footer -->
      <h4></h4>
   </div><!-- /first footer -->
  </div> <!-- /first page -->
 
  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Insulin" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Insulin Prepns   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="a">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> Insulin  </h3>
          <p>  INSULIN: Injection<br><br>
<strong>Ind:</strong> 1. In all cases of Insulin dependent Diabetes mellitus (IDDM)
2. In Non-Insulin dependent Diabetes mellitus (NIDDM) whenever good control with diet and oral hypoglycemic agent is no longer attainable (e.g. secondary failure with sulphonylurea therapy).
3. In malnutrition related Diabetes mellitus (MRDM)
4. In NIDDM subjects whenever special metabolic stresses arise in consequence of operations, febrile illness or accidents (the need of insulin therapy is temporary)
5. During diabetic emergencies such as ketoacidosis, serious breakdown of control.
6. Pregnant diabetic women when diet alone fails to maintain therapeutic goal.<br><br>
<strong>C/I:</strong> Hypoglycaemia. Hypersensitivity to the active substances or to any of the excipients. <br><br><strong>S/E:</strong> Local reactions and lipo-atrophy at the site of injection; overdose causes hypoglycaemia (signs are vomiting specially in children, palpitation, trembling, sweating, tingling in the hands or lip, pallor, impaired visioin, listlessness, confusion and dizziness); lipodystrophy, insulin resistance & hypersensitivity are arely reported with human insulin.<br><br>
<strong>Cautions:</strong> Dosages require proper adjustment druing infections, pregnancy, emotional distress, change in species of origin, type or purity of insulin. Besides insulin requirements may increase during concomitant therapy with thyroxine, corticosteroids & MAOI's may effect insulin requirement.<br><br>
<strong>Dosage & admin:</strong> Adult & Child: By s.c, i.m or i.v injection. Dosage according to individual requirments & initially be determined by the physician. There is no fixed rules for insulin dosage, adjustment in dosages is needed to achieve and maintain desired blood glucose level. The average insulin requirement is between 0.5 to 1 i.0 per kg body wt. per day. Duration: Soluble or short acting insulin approx. 7-8 hours; intermediate acting, approximately 18-24 hours; long acting approximately 24-36 hours.
For dosage, also see in the treatment section.
Mode of administration of Human insulin:
Actrapid HM may be given s.c, i.m or i.v, but Monotard HM, Actraphane HM, Protaphane HM & Ultratard HM are given by s.c injection. Management of Hypoglycaemia:
Glucose should be given orally, or if the patient is unconcious, intravenously.
Glucagon injection may also be administered subcutaneous or intramuscularly.  </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


	  <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> Short Acting Insulin  </h3>
          <p>    </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ACTRAPID Novolet Novo Nordisk/ Transcom  </h3>
          <p> Neutral insulin injection (human monocomponent) 100 i.0/ml; 3ml prefilled syringe.
In this novolet system, prefilled syringe is provided with an ultra thin silicone coated novofine needle. This is virtually a painless and easy way of insulin administration- 'dial and inject method'.
3ml (prefilled syringe) x 5's pack: 2720.00 MRP
INSULIN ACTRAPID HM Novo Nordisk/ Transcom
Neutral insulin injection (human monocomponent) 40 i.0/ml & 100 i.u/ml: injection 40 i.0 x 10m1 vial: 266.00 MRP
100 i.0 x 10ml vial: 561.00 MRP   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  INSULIN ACTRAPID HM (Penfill) Novo Nordisk/Transcom </h3>
          <p> Neutral insulin injection (human monocomponent) 100 i.u/ml.with penfill.3ml cartidge x 5's pack: 1662.00 MRP   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  INSUMAN Rapid Inj. Sanofi Aventis </h3>
          <p> A fast acting regular or soluble human insulin solution 100 i.u/ml: injection
Onset of action within 30 minutes; maximal effect at 1-4 hours; duration of action 7-9 hours.
100 i.0 x 5m1 vial: 259.69 MRP </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


      <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  Medium Acting Insulin </h3>
          <p>    </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  INSULATARD Novolet Novo Nordisk/Transcom </h3>
          <p>   Neutral isophane insulin injection (human monocomponent) 100 i.0/ml; 3ml prefilled syringe.
In this novolet system, prefilled syringe is provided with an ultra thin silicone coated novofine needle. This is virtually a painless and
easy way of insulin administration - 'dial and inject method'.
3m1 (prefilled syringe) x 5's pack: 2720.00 MRP </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSULIN INSULATARD HM Novo Nordisk/Transcom  </h3>
          <p>   Neutral isophane insulin injection (human monocomponent) 40 i.u/ml. and 100 i.u/ml: injection
40 i.0 x 10m1 vial: 266.00 MRP
100 i.0 x 10ml vial: 561.00 MRP </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSULIN INSULATARD HM (Penfill) Novo Nordisk/Transcom  </h3>
          <p>   Neutral isophane insulin injection (human monocomponent) 100 i.0/ml with penfill.
3ml cartidge x 5's pack: 1662.00 MRP </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSULIN MIXTARD 30 HM Novo Nordisk/Transcom  </h3>
          <p>  Biphasic isophane insulin injection (human monocomponent) 30% soluble insulin & 70% isophane insulin; 40 i.0/ml & 100 i.u/ml: injection 40 i.0 x 10ml vial: 266.00 MRP
100 i.0 x 10ml vial: 481.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSULIN MIXTARD 50 HM Novo Nordisk/Transcom  </h3>
          <p>  Biphasic isophane insulin injection (human monocomponent) 50% soluble insulin & 50% isophane insulin; 100 i.u/ml: injection
100 i.0 x 10ml vial: 644.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSULIN MIXTARD 30 HM (Penfill) Novo Nordisk/Transcom  </h3>
          <p>  Biphasic isophane insulin injection (human monocomponent) 30% soluble insulin & 70% isophane insulin; 100 i.0/ml with penfill.
3ml cartidge x 5's pack : 1662.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSULIN MIXTARD 50 HM (Penfill) Novo Nordisk/Transcom  </h3>
          <p>  Biphasic isophane insulin injection (human monocomponent) 50% soluble insulin & 50% isophane insulin; 100 i.0/ml with penfill.
3m1 cartidge x 5's pack : 1662.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSUMAN Basal Inj. Sanofi Aventis   </h3>
          <p>  An intermediate acting human insulin suspension 100 i.u/ml: injection
Onset of action within 60 minutes (gradual); maximal effect at 3-4 hours; duration of action 11- 20 hours.
100 i.0 x 5ml vial: 259.69 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> INSUMAN Comb 25 Inj. Sanofi  </h3>
          <p>  Aventis A combination of short acting and intermediate acting human insulin suspension where 25% regular (soluble) insulin and 75% isophane insulin; 100 i.u/ml: injection.Onset of action within 30-60 minutes (gradual); maximal effect at 2-4 hours; duration of action 12-19 hours (moderately long).
100 i.0 x 5ml vial: 281.70 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> MIXTARD 30 Novolet Novo Nordisk/ Transcom  </h3>
          <p>  Biphasic isophane insulin injection (human monocomponent) 30% soluble insulin & 70% isophane insulin; 100 i.0/ml; 3ml prefilled syringe.
In this novolet system, prefilled syringe is
provided with an ultra thin silicone coated novofine needle. This is virtually a painless and easy way of insulin administration- 'dial and inject method'.
3m1 (prefilled syringe) x 5's pack: 2720.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> MIXTARD 50 Novolet Novo Nordisk/ Transcom  </h3>
          <p>   Biphasic isophane insulin injection (human monocomponent) 50% soluble insulin & 50% isophane insulin; 100 i.0/ml; 3ml prefilled syringe. In this novolet system, prefilled syringe is provided with an ultra thin silicone coated novofine needle.. This is virtually a painless and easy way of insulin administration- 'dial and inject method'.
3m1 (prefilled syringe) x 5's pack: 2720.00 MRP
 </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NOVOMIX 30 Flexpen Novo Nordisk/ Transcom  </h3>
          <p>   Biphasic insulin aspart injection (recombinant human insulin analogue), 30% insulin aspart, 70% insulin aspart protamine, 100 i.0/ml; 3ml prefilled disposable injection devices (flexpen).
3ml (prefilled injection) x 5's pack: 900.00 MRP </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


        <div data-role="collapsible-set" data-theme="b">
          <div data-role="collapsible"> <!-- collapsible -->
            <h3> Long Acting Insulin  </h3>
            <p>    </p>
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
            <h3>  LANTUS Inj. Sanofi Aventis  </h3>
            <p>  Insulin glargine (recombinant human insulin analogue) 100 units/ml; 3m1 cartridge with prefilled injection device: injection
3m1 (prefilled syringe) x 5's: 5128.74 MRP  </p>
          </div><!-- collapsible -->
        </div><!-- collapsible-set -->
      
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Oral hypoglycaemic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Oral hypoglycaemic drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 



<a href="#Sulfonylureas" data-role="button" data-theme="a">Sulfonylureas</a>

<ul data-role="listview" data-inset="true" data-theme="b">        
     
        
        <li><a href="#GLIBENCLAMIDE">GLIBENCLAMIDE</a></li> 
        <li><a href="#GLICLAZIDE">GLICLAZIDE</a></li> 
        <li><a href="#GLIMEPIRIDE">GLIMEPIRIDE</a></li>
        <li><a href="#GLIPIZIDE">GLIPIZIDE</a></li> 
        
         
</ul>

		<!-- ............................... -->

<a href="#" data-role="button" data-theme="a">Biguanides</a>


<ul data-role="listview" data-inset="true" data-theme="b">        
            
     <li><a href="#METFORIVIIN">METFORIVIIN</a></li> 
              
</ul>

		<!-- ............................... -->


<a href="#" data-role="button" data-theme="a">
Other antidiabetic agents</a>


<ul data-role="listview" data-inset="true" data-theme="b">        
            
     <li><a href="#ACARBOSE">Alpha-Glucosidase Inhibitor</a></li>
     <li><a href="#NATEGLINIDE">Meglitinide Analogues</a></li>
     <li><a href="#Thiazolidinedione">Thiazolidinedione Group</a></li>
     <li><a href="#ROSIGLITAZONE">Rosiglitazone</a></li>    
              
</ul>


   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

	

<!-- /................page............................ -->



<div data-role="page" id="GLIBENCLAMIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> GLIBENCLAMIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  GLIBENCLAMIDE: Tablet. </h3>
          <p>  <strong>Ind:</strong> Non-insulin dependent (Type 2) diabetes
mellitus.<br><br>
C/I; S/E; <strong>Cautions:</strong> See above under the text of sulfonylurea.<br><br>
<strong>Pregnancy & lactation:</strong> Sulphonylureas are contra-indicated during pregnancy & breast- feeding, so, a suitable treatment schedule should
be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> Adult: Initially 5mg daily as single dose at breakfast, increasing if necessary by 2.5-5mg at weekly intervals to max. 15 mg daily.
Child: not recommended.<br><br>
Overdose; <strong>Drug Inter:</strong> See above under the text
of sulfonylurea.  </p>
        </div><!-- collapsible -->
  		

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DAONIL Tab. Sanofi Aventis</h3>
  		    <p>Glibenclamide 5mg/tablet.
  		500's pack: 140.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DAOSIN Tab. Gaco</h3>
  		    <p>Glibenclamide 5mg/tablet 100's pack: 28.83 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIBENOL Tab. Square</h3>
  		    <p>Glibenclamide 5mg/tablet 300's pack: 84.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIBEN Tab. Alco Pharma</h3>
  		    <p>Glibenclamide 5mg/tablet 100's pack: 25.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DICON Tab. Jayson</h3>
  		    <p>Glibenclamide 5mg/tablet 100's pack: 24.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLUCON Tab. Opsonin</h3>
  		    <p>Glibenclamide 5mg/tablet 100's pack: 28.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLUCONIL Tab. Acme</h3>
  		    <p>Glibenclamide 5mg/tablet 100's pack: 28.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>SUGANIL Tab. Skylab</h3>
  		    <p>Glibenclamide 5mg/tablet 200's pack: 56.00 MRP</p>   
  		</div><!-- collapsible -->



      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="GLICLAZIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> GLICLAZIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  GLICLAZIDE: Tablet </h3>
          <p> <strong>Ind:</strong> Gliclazide is used alone in Type 2 diabetes patients with diet & exercise after an adequate trial of dietary therapy and exercise that have been proved unsatisfactory. It can also be used in combination with other oral insulin sensitizing drugs like metformin, acarbose & piogliazone, and with insulin when diet, exercise and the above oral hypoglycemic agents do not result in adequate glycemic control.<br><br>
C/I; S/E; <strong>Cautions:</strong> See above under the text of sulfonylurea.<br><br>
<strong>Pregnancy & lactation:</strong> Sulphonylureas are contra-indicated during pregnancy & breast- feeding, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong>
Dosage of 80mg Plain tablet: Initially 40-80mg daily, adjusted according to response; up to 160mg as a single dose with breakfast; higher dose should be given in divided doses; max. 320mg may be given daily.
Dosage of 30mg MR (modified release) tablet/CR (controlled release) capsule: The usual daily dosage is 1 to 4 MR tablets or CR capsules per day as a single dose. It is recommedned that the drug should be taken at breakfast time. The tablets/capsules must be taken whole with half a glass of water just before breakfast. Every administration of tablets/capsules must be followed by a meal.<br><br>
Overdose; <strong>Drug Inter:</strong> See above under the text of sulfonylurea.   </p>
        </div><!-- collapsible -->
  

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>COMPRID XR Tab. Square</h3>
            <p>Gliclazide 30mg/tablet (extended release). 30's pack: 180.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CONSUCON Tab. Incepta</h3>
            <p>Glicla 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CONSUCON MR Tab. Incepta</h3>
            <p>Gliclazide 30mg/tablet (modified release). 30's pack: 180.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DELA Tab. Mystic</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIAB Tab. Rephco</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIABID Tab. Cosmic</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 275.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIACON Tab. Apex</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 225.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIACON-80 Tab. Millat</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 303.50 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIAGLE Tab. Aexim</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 225.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIAMICRON MR Tab. Servier</h3>
            <p>Gliclazide 30mg/tablet (modified release). 30's pack: 264.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIAPRID Tab. Alco Pharma</h3>
            <p>Gliclazide 80mg/tablet 30's pack: 135.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIAPRO Tab. Beximco</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIATROL Tab. Pacific</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 400.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIATROL MR Tab. Pacific</h3>
            <p>Gliclazide 30mg/tablet (modified release). <strong>Ind:</strong> See above.
        50's pack: 400.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIGREEN Tab. Nipa</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 225.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIMEROL Tab. Drug Inter.</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIMEROL-MR Tab. Drug Inter.</h3>
            <p>Gliclazide 30mg/tablet (modified release). <strong>Ind:</strong> See above.
        50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>EZIDE Tab. Edruc</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 300.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GIDE Tab. Medicon</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLAD Tab. Novartis</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 275.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLICA-AT Tab. Modern</h3>
            <p>Gliclazide 80mg/tablet 40's pack: 175.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLICASIL Tab. Silva</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLICLID Tab. Acme</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLICRON Tab. Renata</h3>
            <p>Gliclazide 80mg/tablet 30's pack: 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLICRON CR Cap. Renata</h3>
            <p>Gliclazide 30mg/capsule (controlled release). 30's pack: 180.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLIMICRON Tab. White Horse</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLIMICRON MR Tab. White Horse</h3>
            <p>Gliclazide 30mg/tablet (modified release). 30's pack: 264.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLITAB Tab. Hudson</h3>
            <p>Gliclazide 80mg/tablet 100's pack: 450.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLIZID Tab. Opsonin</h3>
            <p>Gliclazide 80mg/tablet 20's pack: 120.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLIZID MR Tab. Opsonin</h3>
            <p>Gliclazide 30mg/tablet (modified release). <strong>Ind:</strong> See above.
        30's pack: 180.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLUCOSTAT Tab. Bio-pharma</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 225.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLUCOZID Tab. Aristopharma</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLUZIT Tab. Popular-</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 275.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GORED Tab. General</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GORED MR Tab. General</h3>
            <p>Gliclazide 30mg/tablet (modified release). <strong>Ind:</strong> See above.
        28's pack: 168.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>KEZID Tab. Chemico</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>LOZIDE Tab. ACI</h3>
            <p>Gliclazide 80mg/tablet 40's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>OCLAZID Tab. Orion</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ORAZID Tab. Somatec</h3>
            <p>Gliclazide 80mg/tablet 30's pack: 150.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PROGLID Tab. Supreme</h3>
            <p>Gliclazide 80mg/tablet 30's pack: 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>SINAZID Tab. Ibn Sina</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>SUCOTAB Tab. Globe</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 225.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>XIDO Tab. Delta</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 250.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ZENZIDE Tab. Zenith</h3>
            <p>Gliclazide 80mg/tablet 30's pack: 150.00 MRP 100's pack: 500.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ZIDE Tab. Pharmadesh</h3>
            <p>Gliclazide 80mg/tablet 50's pack: 187.50 MRP</p>   
        </div><!-- collapsible -->



      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="GLIMEPIRIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> GLIMEPIRIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> GLIMEPIRIDE: Tablet  </h3>
          <p>   Glimepiride is a newer long-acting sulphonylurea. <br><br><strong>Mode of action:</strong> Glimepiride appears to lower blood glucose level acutely by stimulating the release of insulin from the functioning pancreatic beta-cells. In addition, extrapancreatic effects may also play a role in the activity of sulfonylureas, that glimepiride administration can lead to increased sensitivity of peripheral tissues to insulin.<br><br>
<strong>Ind:</strong> Glimepiride is used alone in type 2 diabetes patients with diet & exercise after an adequate trial of dietary therapy and exercise that have been proved unsatisfactory. It can also be used in combination with other oral insulin sensitizing drugs like metformin, acarbose & piogliazone, and with insulin when diet, exercise and the above oral hypoglycemic agents do not result in adequate glycemic control.<br><br>
C/I; <strong>S/E:</strong> See above under the text of sulphonylurea.<br><br>
Pre<strong>Cautions:</strong> In the initial weeks of treatment, the risk of hypoglycemia may be increased and careful monitoring is essential. If such risk is present it may be necessary to adjust the dosage of glimepiride. Hypoglycemia can almost always be promptly controlled by immediate intake of carbohydrates (glucose or sugar e.g, in the form of sugar lumps, sugar-sweetened fruit juice or sugar- sweetened tea). Caution in renal insufficiency and obese patients.<br><br>
<strong>Pregnancy & lactation:</strong> Sulphonylureas are contra-indicated during pregnancy & breast- feeding, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> The dosage of glimepiride must be the lowest one, which is sufficient to achieve the desired metabolic control. The usual initial dose is 1mg once daily. If necessary, the daily dose can be increased. Any increase should be based on regular blood sugar monitoring, and gradual, i.e at intervals of one to two weeks, and carried out stepwise as follows- 1mg-2mg-3mg-4mg-6mg. In patients with well controlled diabetes, the usual dose range is 1 to 4mg daily. Normally, a single daily dose is sufficient. This should be taken immediately before a substantial breakfast or- if none is taken- immediately before the first main meal, with sufficient amounts of liquld (approximately half glass). It is very important not to skip meals after taking the drug. Secondary dosage adjustment- as the contr of of diabetes improves, sensitivity to insulin increases; therefore, glimepiride requirement may fall as treatment proceeds. To avoid hypoglycemia, timely dose reduction or cessation of glimepiride therapy must be considered. A dose adjustment must also be considered whenever the patient's weight or life-style changes, or other factors arise which cause an increased susceptibility to hypo- or hyperglycemia.
When substituting glimepiride for other oral diabetic agents, the initial daily dose is lmg, this applies even in changeover from the maximum dose of the drug.
Overdose;<br><br> <strong>Drug Inter:</strong> See above under the text of sulfonylurea. </p>
        </div><!-- collapsible -->
  		
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ADGLIM Tab. UniMed & UniHealth</h3>
  		    <p>Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 90.00 MRP 2mg x 30's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>  AMARYL Tab. Sanofi Aventis </h3>
                <p>  Glimepiride INN 1mg, 2mg & 3mg/tablet 1mg x 30's pack: 184.20 MRP
      2mg x 30's pack: 360.00 MRP
      3mg x 30's pack: 465.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DACTUS Tab. Acme </h3>
                <p>  Glimepiride INN 1mg & 2mg/tablet
      1mg x 50's pack: 150.00 MRP
      2mg x 40's pack: 200.00 MRP </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DIALON Tab. SK+F  </h3>
                <p> Glimepiride INN 1mg, 2mg & 4mg/tablet 1mg x 50's pack: 125.00 MRP
      2mg x 30's pack: 120.00 MRP
      4mg x 20's pack: 120.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DIARYL Tab. Beximco  </h3>
                <p>  Glimepiride INN 1mg, 2mg & 3mg/tablet 1mg x 30's pack: 75.00 IP
      2mg x 30's pack: 135.00 IP
      3mg x 30's pack: 195.00 IP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DIETA Tab. Pacific </h3>
                <p> Glimepiride INN 1mg, 2mg & 4mg/tablet 1mg x 30's pack: 90.00 MRP
      2mg x 30's pack: 150.00 MRP
      4mg x 30's pack: 240.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GIPID Tab. Alco Pharma  </h3>
                <p>  Glimepiride INN 1 mg & 2mg/tablet
      1mg x 30's pack: 75.00 MRP 2mg
      x 30's pack: 120.00 MRP
        </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLEMEP Tab. Healthcare  </h3>
                <p> Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 90.00 MRP
      2mg x 30's pack: 150.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLIMIRID Tab. ACI </h3>
                <p>  Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 90.00 MRP
      2mg x 30's pack: 150.00 MRP </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>  GLIMS Tab. Opsonin </h3>
                <p> Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 90.00 MRP
      2mg x 30's pack: 150.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUCONOR Tab. Aristopharma </h3>
                <p> Glimepiride INN 1mg & 2mg/tablet 1mg x 50's pack: 150.00 MRP 2mg x 30's pack: 150.00 MRP
         </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUTIM Tab. Techno Drugs </h3>
                <p>  Glimepiride INN 1mg/tablet
      1mg x 30's pack: 90.00 MRP </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> LIMARYL Tab. Popular  </h3>
                <p>  Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 90.00 IP 2mg x 30's pack: 150.00 1P  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> LIMERID Tab. Supreme  </h3>
                <p>  Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 184.20 MRP 2mg x 30's pack: 360.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> LIMPET Tab. Drug Inter. </h3>
                <p> Glimepiride INN 1mg & 2mg/tablet 1mg x 50's pack: 150.00 MRP 2mg x 50's pack: 200.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> LOSUCON Tab. Incepta  </h3>
                <p>  Glimepiride INN I mg & 2mg/tablet
      1mg x 50's pack: 100.00 MRP
      2mg x 50's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> MEPID Tab. Renata  </h3>
                <p>  Glimepiride INN 1mg, 2mg & 4mg/tablet 1mg x 30's pack: 75.00 MRP
      2mg x 30's pack: 120.00 MRP 4mg x 30's pack: 210.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> PRIDE Tab. White Horse </h3>
                <p> Glimepiride INN 1mg, 2mg & 4mg/tablet
      1mg x 50's pack: 150.00 MRP
      2mg x 50's pack: 250.00 MRP
      4mg x 30's pack: 240.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>  SECRIN Tab. Square </h3>
                <p>  Glimepiride INN 1mg, 2mg, 3mg & 4mg/tablet 1mg x 30's pack: 90.00 MRP 2mg x 30's pack: 150.00 MRP 3mg x 30's pack: 210.00 MRP 4mg x 30's pack: 240.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> STIMULIN Tab. Orion  </h3>
                <p>  Glimepiride INN 1mg & 2mg/tablet 1mg x 30's pack: 90.00 MRP
      2mg x 30's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="GLIPIZIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> GLIPIZIDE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> GLIPIZIDE: Tablet  </h3>
          <p>  <strong>Ind:</strong> Glipizide is used alone in Type 2 diabetes patients with diet & exercise after an adequate trial of dietary therapy and exercise that have been proved unsatisfactory. It can also be used in combination with other oral insulin sensitizing drugs like metformin, acarbose & piogliazone, and with insulin when diet, exercise and the above oral hypoglycemic agents do not result in adequate glycemic control.<br><br>
C/I; S/E; <strong>Cautions:</strong> See above under the text of sulphonylurea.<br><br>
<strong>Pregnancy & lactation:</strong> Sulphonylureas are contra-indicated during pregnancy & breast- feeding, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> Initially 2.5-5mg daily, adjusted according to response; max. 40mg daily; upto 15mg may be given as a single dose before breakfast; higher doses divided.
For maximum effect in reducing postprandial hyperglycemia, glipizide should be ingested 30 minutes before breakfast, since rapid absorption is delayed when the drug is taken with food.<br><br>
Overdose; <strong>Drug Inter:</strong> See above under the text of sulfonylurea.  </p>
        </div><!-- collapsible -->
  		


  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ACTINE Tab. Aristopharma</h3>
  		    <p>Glipizide 5mg/tablet 5mg x 50's pack: 100.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIACTIN Tab. Beximco</h3>
  		    <p>Glipizide 5mg/tablet
  		5mg x 100's pack: 150.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAPIZI Tab. Medimet</h3>
  		    <p>Glipizide 2.5mg & 5mg/tablet 2.5mg x 100's pack: 100.00 MRP 5mg x 100's pack: 200.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAPLUS Tab. Pacific</h3>
  		    <p>Glipizide 5mg/tablet 5mg x 45's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAPLUS XR 5/10 Tab. Pacific</h3>
  		    <p>Glipizide 5mg & 10mg/tablet (extended release). 5mg x 30's pack: 84.00 MRP 10mg x 30's pack: 120.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLIMEROL Tab. Drug Inter.</h3>
  		    <p>Glipizide 5mg/tablet 5mg x 100's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> ZITROL XR Tab. Square </h3>
                <p>  Glipizide 2.5mg, 5mg & 10mg/tablet (extended release).
      2.5mg x 30's pack: 45.00 MRP
      5mg x 50's pack: 100.00 MRP
      10mg x 30's pack: 90.00 MRP  </p>
              </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Sulfonylureas" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Sulfonylureas   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      
          <p> The sulfonylureas are the most widely used oral antidiabetic agents for the treatment of Type 2 diabetes mellitus (Non-insulin-dependent diabetes mellitus- NIDDM).<br><br>
<strong>Pregnancy & lactation:</strong> The mode of action of the sulphonylureas include- i. stimulation of insulin release from the functioning b-cells of the pancreas, ii. increasing ser sitivity of peripheral tissues & receptors to insulin (during long-term administration), & iii. reduction of serum glucagon levels.<br><br>
<strong>Ind:</strong> See below under the individual preparation.<br><br> <strong>C/I:</strong> Insulin dependent (Type 1) diabetes mellitus; diabetic precoma or coma. Hypersensitivity to sulfonylureas, and other sulfonamides. Patients with severe renal or hepatic impairment; endocrine disorders; stress, infection; surgical procedure. <br><br>Pregnancy & lactation
<strong>S/E:</strong> Hypoglycaemic manifestations- such as sweating, pallor, intense hunger, malaise, temporary vival impairment. Other side-effects include gastro- intestinal disturbances, such as anorexia, nausea, vomiting, epigastric discomport; others may include weakness, paraesthesia, sensitivity reactions including fever, rashes, jaundice, headache. Very rarely blood disorders, which may include thrombocytopenia, agranulocytosis, and aplastic anaemia. Patients on sulfonylurea therapy may develop facial flushing after alcohol drinking.
Adnormal laboratory results affecting blood and
liver functions.<br><br>
Pre<strong>Cautions:</strong> Hepatic & renal insufficiency; obese patients. Elderly patients should avoid long-acting sulphonylureas (e.g chlorpropamide), as it may cause hypoglycaemia.
Warnings: Hypoglycaemia: This medicine is susceptible to cause episodes of hypoglycaemia (decrease of blood sugar levels); in the case of sweating, intense hunger, trembling, pallor, visual disturbances, feeling of malaise, abnormal behavior, immediately eat sugar or something containing sugar and inform your physician. Hypoglycaemia is favoured by a strict or poorly balanced diet, by prolonged or strenuous exercise, by the intake of alcohol or during use of other hypoglyca-emic drugs (see drug interactions below).
In consequence, treatment with a hypoglycaemic sulphonylurea requires: i. a regular diet- it is important to eat regular meals, including breakfast, never miss a meal; ii. Precise regularity in treatment- it is important to take the treatment regularly.
<br><br><strong>Pregnancy & lactation:</strong> In case of pregnancy diabetes should be treated with insulin. In case of suspecting or diagnosing a new pregnancy while taking oral diabetic medication, stop the therapy immediately, and prescribe a more suitable treatment schedule with insulin for the rest period of pregnancy.
In case of desired pregnancy, a suitable treatment
ï¿¼
schedule should be prescribed with insulin Sulphonylureas are also contra-indicated when breast-feeding, so, a suitable treatment schedule should be prescribed with insulin during the nursing period.
Dosage & amdin: See below under the text of individual preparations.
Advices to the patients: Follow as closely as possible the dietary advice & medicine prescribed by the doctor. Regularly carry out the laboratory tests as advised you. Inform your physician in different conditions, such as- in the case of surgery, trauma, fever or infection, difficult
eating; in the case of a planned pregnancy; in the case of taking other drugs, particularly an anti- inflammatory agent, beta-blocker, corticosteroid. Overdose: The administration of an excessive dose of any sulphonylurea results in hypoglycaemia (see warnings) whcih should be treated immediately by the administration of sugar (4 to 6 lumps). In severe cases, if there is clouding of consciousness, 10%-30% hypertonic glucose solution must be administered intravenously without delay and the patient should be transferred to the hospital immediately.
Missing dose: In case of forgotten or missing one or more doses-
do not take a double dose to compensate or the single dose that is forgotten or missed to take. Take the regular dose in regular time.<br><br>
<strong>Drug Inter:</strong> The hypoglycemic effect of sulphonylureas may be potentiated by NSAID particularly aspirin, phenylbuta-zone, sulphonamides, coumarin derivatives, MAOIs, b-adrenergic blockers, H2 antagonists e.g cimetidine, tetracyclines, chloramphenicol, clofibrate, and anti-fungal oral agents like miconazole & fluconazole. Ingestion of alcohol may also increase the hypoglyce-mic effect of gliclazide.
Some drugs, on the contrary, may reduce its activity e.g barbiturates, corticoste-roids, thiazide diuretics, thyroid hormones, phenytoin, laxatives and oral contraceptives.   </p>
       
  

     
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="METFORIVIIN" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> METFORIVIIN   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  METFORMIN HCI: Tablet/Oral solution. </h3>
          <p>   Metformin is a biguanide antihyperglycemic agent which improves glucose tolerance to Type 2 diabetes patients by lowering basal and post- prandial plasma glucose.<br><br>
<strong>Mode of action:</strong> Metformin inhibits hepatic glucose production (gluconeogenesis), reduces intestinal absorption of glucose, and improves peripheral insulin sensitivity (increases peripheral glucose uptake & utilization). Unlike sulfonylureas, metformin does not produce hypoglycemia in either diabetic or non-diabetic subjects. Metformin helps lower cholesterol level and also helps obese patient to lose weight. <br><br><strong>Ind:</strong> In non-insulin dependent (Type 2) diabetes mellitus- alone, when blood glucose & obesity are not responding to dietary therapy; in combination with a sulfonylurea, repaglinide, pioglitazone, acarbose, or insulin.<br><br>
Adjuvant therapy in insulin-dependent (Type 1) diabetes, particularly in the obese.
<strong>C/I:</strong> Individual hypersensitivity to metformin, renal impairment, liver disease, predisposition to lactic acidosis, heart failure, severe infection or trauma, dehydration and alcohol dependence. Metformin is not advised during pregnancy & lactation; and not for pediatric use.<br><br>
<strong>S/E:</strong> Normally well tolerated but hypoglycaemic attack may occur especially in elderly, debilitated or traumatised cases. Lactic acidosis is a very rare occurence (0.003%), when the patient taking metformin over the course of a year, the symptoms are anorexia, nausea, vomiting, fever increased respiratory rate, malaise, abdominal pain, diarrhea. It may induce malabsorption of vitamin B12, folic acid & elevate liver enzymes.<br><br> <strong>Cautions:</strong> Metformin should only be prescribed when diet and weight reducton has proven inadequate. During concomitant therapy with other oral hypoglycemic drugs, blood sugar should be monitored carefully because combined therapy may cause hypoglycemia. Patient must be colsely monitored in order to identify any factor or condition that may favour the onset of lactic acidosis. The risk of lactic acidosis is higher among the patients over 60. Patients shouldbe instructed how to recognize the early symptoms of lactic acidosis (see above inder side-effects). In the event of severe trauma, injuries, infectious diseases & high fever, and surgery, it may be necessary to give insulin to maintain adequate metabolic control. Caution in excess alcohol intake. <br><br><strong>Pregnancy & lactation:</strong> Metformin is not recommended during pregnancy and breast- feeding, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> Adult: Initially 500mg twice daily or 850mg daily with meals increasing gradually if necessary to maximum 3gm daily. Reduce to maintenance, usually 500mg thrice or 850mg twice daily.
Child: Not applicable
Dosage of ER, LA, SR or XR preparations: The usual starting dose of ER, LA, SR or XR 500mg (metformin hydrochloride- long acting or extended release) is one tablet once daily with the evening meal. Dosage can be increased with a rate of 500mg weekly, up to a maximum of 2000mg once daily with the evening meal. If glycemic control is not achieved ER, LA, SR or XR 2000mg once daily, a trial of ER, LA, SR or XR 1000mg twice daily should be
considered.<br><br>
<strong>Drug Inter:</strong> Nifedipine appears to enhance the absorption of metformin but the latter has minimal effects on nifedipine. Thiazides, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid tend to produce hyperglycemia and may lead to loss of glycemic control. Metformin may enhance the effects of anti-coagulants. </p>
        </div><!-- collapsible -->
  			


  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>BIGMET Tab. Renata</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 100.00 MRP
  		850mg x 100's pack: 250.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>COMET Tab. Square</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 200.00 MRP
  		850mg x 50's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>COMET XR 500 Tab. Square</h3>
  		    <p>Metformin hydrochloride 500mg/tablet (extended release).
  		500mg x 50's pack: 200.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>COMET XR 1gm Tab. Square</h3>
  		    <p>Metformin hydrochloride 1gm/tablet (extended release).
  		1gm x 30's pack: 210.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>COMET Oral Soln. Square</h3>
  		    <p>Metformin hydrochloride 500mg/5ml: Oral solution.
  		100ml bot: 60.00 MRP
  		200m1 bot: 110.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DAOMIN Tab. Acme</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 200.00 MRP
  		850mg x 40's pack: 120.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIABEX Tab. Gaco</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 55.50 MRP
  		850mg x 30's pack: 82.68 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAFRE Tab. Mystic</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 150.00 MRP
  		850mg x 50's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DIA-M Tab. Medimet  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 110.00 MRP
      850mg x 100's pack: 250.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> DIA-M SR Tab. Medimet  </h3>
                <p> Metformin hydrochloride 500mg/tablet (sustained release). 500mg x 100's pack: 200.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>ETFORM Tab. Novartis  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 200.00 MRP 850mg x 50's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> FORMET Tab. Bio-pharma  </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 110.00 MRP 850mg x 50's pack: 125.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> FORMIN Tab. Skylab  </h3>
                <p>  Metformin hydrochloride 850mg/tablet
      850mg x 30's pack: 90.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> FORMIN Tab. Zenith </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 150.00 MRP
      850mg x 100's pack: 300.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>  GLIMET-850 Tab. Millat  </h3>
                <p> Metformin hydrochloride 850mg/tablet
      850mg x 30's pack: 90.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUCOMET Tab. Aristopharma  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 200.00 MRP
      850mg x 50's pack: 150.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUCOMET 500 XR Tab. Aristopharma </h3>
                <p> Metformin hydrochloride 500mg/tablet (extended release).
      500mg x 50's pack: 200.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUCOMET 750 XR Tab. Aristopharma  </h3>
                <p>  Metformin hydrochloride 750mg/tablet (extended release).
      500mg x 30's pack: 180.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUNOR Tab. SK+F  </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 100.00 MRP
      850mg x 50's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUNOR XR Tab. SK+F </h3>
                <p> Metformin hydrochloride 500mg/tablet (extended release). 500mg x 50's pack: 200.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLUPHAGE XR Tab. Silva  </h3>
                <p>Metformin hydrochloride 400mg/tablet (extended release). 400mg x 50's pack: 185.00 MRP    </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLYMIN Tab. Healthcare  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 75.00 MRP
      850mg x 40's pack: 120.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GLYMIN 500 XR Tab. Healthcare </h3>
                <p> Metformin hydrochloride 500mg/tablet (extended release).
      500mg x 50's pack: 230.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>G-PHASE Tab. Edruc   </h3>
                <p> Metformin hydrochloride 850mg/tablet
      850mg x 30's pack: 90.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> HI-MET Tab. Hudson  </h3>
                <p>  Metformin hydrochloride 850mg/tablet
      850mg x 100's pack: 300.00 IP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> INFO Tab. Bristol </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 100.00 MRP
      850mg x 50's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> INFORMET Tab. Beximco   </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 110.00 IP 850mg x 60's pack: 150.00 IP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> INFORMET LA Tab. Beximco  </h3>
                <p> Metformin hydrochloride BP 500mg /tablet (long acting).
      500mg x 100's pack: 400.00 IP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> INSIMET Tab. Ibn Sina  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 110.00 MRP 850mg x 50's pack: 125.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> KEMIN Tab. Chemico  </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 150.00 MRP
      850mg x 50's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> MEGLU Tab. UniHealth/UniMed  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 30's pack: 60.00 MRP 850mg x 30's pack: 90.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> MEGLU ER-500 Tab. UniHealth/UniMed </h3>
                <p> Metformin hydrochloride 500mg/tablet (extended release).
      500mg x 30's pack: 150.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> MET Tab. Opsonin  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 30's pack: 33.00 MRP
      850mg x 30's pack: 75.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METARIN Tab. Popular  </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet 500mg x 30's pack: 60.00 IP 850mg x 30's pack: 90.00 IP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METFAR Tab. White Horse </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 100.00 MRP 850mg x 50's pack: 150.00 MRP </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METFAR SR Tab. White Horse  </h3>
                <p>  Metformin hydrochloride 500mg & 1000mg/tablet (sustained release).
      500mg x 50's pack: 200.00 MRP
      1000mg x 30's pack: 210.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METFAST ER 500 Tab. Aexim  </h3>
                <p>  Metformin hydrochloride 500mg/tablet (extended release).
      500mg x 50's pack: 200.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METFEN Tab. Doctor's </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 101.00 MRP 850mg x 50's pack: 125.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METFO Tab. Pacific  </h3>
                <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 125.00 MRP
      850mg x 30's pack: 120.00 MRP    </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>METFO XR 500/1000 Tab. Pacific   </h3>
                <p> Metformin hydrochloride 500mg/tablet & 1000mg/tablet (extended release).
      500mg x 30's pack: 150.00 MRP
      1000mg x 30's pack: 270.00 MRP   </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METFORM Tab. ACI </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet (f.c).
      500mg x 100's pack: 110.00 MRP
      850mg x 50's pack: 125.00 MRP </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METIN Tab. Supreme  </h3>
                <p>  Metformin hydrochloride 500mg & 850mg/tablet. 500mg x 50's pack: 75.00 MRP
      850mg x 30's pack: 90.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METMIN-850 Tab. Alco Pharma  </h3>
                <p>  Metformin hydrochloride 850mg/tablet
      100's pack: 225.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> METOMIN Tab. Somatec </h3>
                <p> Metformin hydrochloride 850mg/tablet 50's pack: 125.00 IP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3>   MINIFOR Tab. Rephco </h3>
                <p>  Metformin hydrochloride 850mg/tablet
      100's pack: 380.00 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> NOBESIT Tab. Incepta  </h3>
                <p> Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 50.00 MRP
      850mg x 50's pack: 125.00 MRP   </p>
              </div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NOBESIT Tab. Incepta</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 50.00 MRP
  		850mg x 50's pack: 125.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NOBESIT XR 500 Tab. Incepta</h3>
  		    <p>Metformin hydrochloride 500mg/tablet (extended release).
  		500mg x 50's pack: 200.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>OBID 500 Tab. Delta</h3>
  		    <p>Metformin hydrochloride 500mg/tablet
  		500mg x 100's pack: 200.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>OBID 850 Tab. Delta</h3>
  		    <p>Metformin hydrochloride 850mg/tablet
  		850mg x 30's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ORAMET Tab. Drug Inter.</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 200.00 MRP
  		850mg x 100's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ORAMET-SR Tab. Drug Inter.</h3>
  		    <p>Metformin hydrochloride 500mg/tablet (sustained release).
  		500mg x 50's pack: 200.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ORMIN Tab. Orion</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 55.00 MRP
  		850mg x 50's pack: 125.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>P-MIN Tab. Pharmadesh</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 110.00 MRP
  		850mg x 30's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREFORM-850 Tab. Apex</h3>
  		    <p>Metformin hydrochloride 850mg/tablet
  		850mg x 100's pack: 250.00 MRP</p>   
  		</div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> PREFORM-SR Tab. Apex </h3>
                <p> Metformin hydrochloride 500mg/tablet (sustained release).
      500mg x 50's pack: 200.00 MRP  </p>
              </div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREFORM Soln. Apex</h3>
  		    <p>Metformin hydrochloride 500mg/5ml: oral solution.
  		100ml bot: 60.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>SUCOMET Tab. Globe</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 100.00 MRP
  		850mg x 50's pack: 115.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>SUGAMET Tab. General</h3>
  		    <p>Metformin hydrochloride 500mg & 850mg/tablet 500mg x 100's pack: 120.00 MRP
  		850mg x 40's pack: 120.00 MRP</p>   
  		</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="ACARBOSE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Alpha-Glucosidase inhibitor  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ACARBOSE  </h3>
          <p> Acarbose is an oral hypoglycaemic agent. Mode of acation: It inhibits intestinal ô°- glucosidase enzyme with resultant reduction in carbohydrate digestion and absorption. It slows down the digestion of carbohydrates & lengthens the time it takes for carbohydrate to convert to glucose (i.e convertion of disaccharide into monosaccharides), thereby facilitates better blood glucose control. It mainly influences the level of blood sugar after earting, and hence flattens post
ï¿¼meal rises in glucose and insulin levels. It is also believed that acarbose improves insulin sensitivity & prevents or delays the progressive deterioration in pancreatic b-cells that routinely occurs in patients with Type II Diabetes mellitus.<br><br>
<strong>Ind:</strong> Acarbose as monotherapy, is indicated as an adjunct to diet to lower blood glucose in patients with type II diabetes mellitus (NIDDM) whose hyperglycaemia can not be managed on diet alone. It may also be used in combination with a sulfon- ylurea when diet plus either acarbose or a sulfony- lurea do not result an adequate glycaemic control. <br><br><strong>C/I:</strong> Known hypersensitivity to the drug. Since the information on its effects and tolerability in children and adolescents is still insufficient it should not be used in patients under 18 years of age. Chronic inflammatory & other bowel disorders associated with distinct disturbances of digestion and absorption (e.g. ulcerative colitis, Crohn's disease). States which may deteriorate as a result of increased gas formation in the intestine (e.g. Roemheld's syndrome, major hernias, intestinal obstruction and intestinal ulcers). Acarbose should not be administered during pregnancy & lactation, as no information is available on its use in these conditions in humen. Acarbose should not be used in patients with severe renal impairment (creatinine clearance less than 25ml/min).<br><br>
<strong>S/E:</strong> Frequently flatulence and bowel sounds, occasionally diarrhoea and abdominal distension and less frequently abdominal pain. These side effects may be severe and might be confused with ileus or ileus-like symptoms. If the prescribed diabetic diet is not maintained the intestinal side effects may be intensified. If strongly distressing symptoms develop in spite of maintaining diabetic diet prescribed, the doctor must be consulted and the dose may temporarily or permanently be reduced. In individual cases hypersensitive skin reactions may occur e.g erythema, exanthema and urticaria. Very rarely, hepatitis and/or jaundice have been reported.<br><br>
Warnings & Pre<strong>Cautions:</strong> Asymptomatic liver enzyme elevations may occur in individual cases specially at higher dosages. Therefore, appropriate liver enzyme monitoring should be considered during the first 6 to 12 months of treatment. In evaluable cases these changes were reversible on discontinuation of the drug.<br><br>
<strong>Pregnancy & lactation:</strong> Acarbose is not recommended during pregnancy and breast- feeding, so, a suitable treatment schedule should
be prescribed with insulin.
Dosage: Starting dosage: 25mg 3 times daily with meals. Usual dosage: 50-100mg 3 times daily or as the number of meals, depending on the patient's weight and tolerance of side- effects. Some patients may benefit from gradual dose adaptation by initiating treatment at 50mg once a day for 1 or 2 weeks, then 50mg twice a day for 1 or 2 weeks followed by 50mg three times a day. If necessary, dose can be increased to 100mg three times a day depending on the clinical response. Acarbose is to be taken orally, chewed with the first mouthful of food, or swallowed whole with a little liquid directly before the meal. Patients should be encouraged to follow their dietary guidelines and avoid sucrose. In elderly
ï¿¼
patients no dosage adjustment is required. Acarbose shoud not be interrupted without consulting a physician as this can lead to a rise in blood glucose.<br><br>
<strong>Drug Inter:</strong> Sucrose (cane sugar) and foods containing sucrose often cause abdominal discomfort or even diarrhoea during treatment with acarbose as a result of increased carbohydrate fermentation in the colon. Acarbose has an antihyperglycaemic effect, but does not itself induce hypoglycaemia. If acarbose is prescribed in addition to sulphonylurea or metformin, or in addition to insulin, a fall of the blood glucose level into the hypoglycaemic range may necessitate a suitable decrease in the sulphonylurea, metformin or insulin dose. If acute hypoglycaemia develops it should be borne in mind that sucrose (cane sugar) is broken down into fructose and glucose more slowly during treatment with acarbose, for this reason sucrose is unsuitable for a rapid alleviation of hypoglycaemia and glucose should be used instead. Simultaneous administration of cholestyramine, intestinal adsorbents, and digestive enzyme products should be avoided as they may possibly influence the action of acarbose. Certain other drugs tend to produce hyperglycaemia and may lead to loss of blood glucose control, such as, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazides.   </p>
        </div><!-- collapsible -->
  		
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>SUGATROL Tab. Pacific</h3>
  		    <p>Acarbose INN 50mg & 100mg/tablet. 50mg x 30's pack: 300.00 MRP 100mg x 30's pack: 450.00 MRP</p>   
  		</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="NATEGLINIDE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Meglitinide Analogues  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NATEGLINIDE  </h3>
          <p> Nateglinide is an oral blood glucose-lowering drug belonging to a new class of insulinotropic agents called meglitinide analog (a carbamomethyl benzoic acid- CMBA derivative). <br><br><strong>Ind:</strong> Treatment of patients with Type-2 diabetes, whose hyperglycaemia can not be controlled by diet and physical exercise. Nateglinide can be used as monotherapy or in combination with other oral antidiabetic agents with a complementary mode of action, such as metformin and troglitazone.<br><br>
<strong>C/I:</strong> Hypersensitivity to nateglinide or to any of the excipients, Type-1 diabetes, diabetic
ketoacidosis, pregnancy and lactation.<br><br>
<strong>S/E:</strong> Hypoglycaemia; rare cases of elevations in liver enzymes and hypersensitivity reactions. Precautions & Warnings: Hypoglycaemia has been observed in patients with Type-2 diabetes on diet and exercise, and in those treated with oral antidiabetic agents. Elderly, malnourished patients and those with adrenal or pituitary insufficiency are more susceptible to the glucose lowering effect of these treatments. The risk of hypoglycaemia in Type-2 diabetic patients may be increased by strenuous physical exercise, or ingestion of alcohol. Combination with other oral antidiabetic agents may increase the risk of hypoglycaemia. Hypoglycaemia may be difficult to recognise in subjects receiving b-blockers.<br><br> <strong>Pregnancy & lactation:</strong> Nateglinide is not recommended during pregnancy and lactation, so, a suitable treatment schedule should be prescribed with insulin.
Dosage: The usual dose is 120mg before main meals.<br><br>
<strong>Drug Inter:</strong> The hypoglycaemic action of oral antidiabetic agents may be potentiated by certain drugs, including non-steroidal anti-inflammatory agents, salicylates, monoamine oxidase inhibitors, and non-selective b-adrenergic-blocking agents. The hypoglycaemic action of oral antidiabetic agents may be reduced by certain drugs, including thiazides, corticosteroids, thyroid products and sympathomimetics.
Note: Before prescribing, please consult full prescribing information.   </p>
        </div><!-- collapsible -->
  
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NOPIK Tab. Square</h3>
            <p>Nateglinide 120mg/tablet. 30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>STARLIX Tab. Novartis</h3>
            <p>Nateglinide 120mg/tablet. 84's pack: 2155.44 MRP</p>   
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->


<!-- /............................................ -->

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> REPAGLINIDE  </h3>
          <p> Repaglinide is an oral blood glucose-lowering drug belonging to a new class of insulinotropic agents (secretagogue) called meglitinide analog (a carbamomethyl benzoic acid- CMBA derivative). It is used in the management of Type 2 diabetes mellitus (NIDDM).<br><br>
<strong>Mode of action:</strong> In Type 2 diabetes, the characteristic defect is 'failure of mealtime insulin response, which is usually slow and insufficient'. When repaglinide is taken prior to meals, it rapidly corrects mealtime insulin secretion abnormalities in Type 2 diabetes (NIDDM) and causes disposal of the mealtime glucose load. Repaglinide, as selectively stimulates insulin secretion in response to high glucose level in the prandial phase, which in turn controls blood glucose peaks- called 'prandial glucose regulation (PGR)'- is a novel concept in NIDDM management. Repaglinide does not stimulate insulin release from the beta cells in the post- prandial fasting period i.e in the absence of excess glucose. After oral administration, repaglinide is rapidly and completely absorbed from the gut - as the serum concentration increases, its rapid onset and relatively short duration of action on b-cells the plasma insulin level rises immediately and usually returns to baseline before the next mealtime. Rapid elimination ensures that post- prandial insulin levels quickly returns to pre- prandial levels as the high prandial glucose level subsides. Repaglinide allows the pancreas of a person with NIDDM to respond to meal-related increase in blood glucose level in a similar manner of the pancreas of a healthy person without diabetes.
<br><br><strong>Ind:</strong> Repaglinide is indicated in Type 2 diabetes mellitus (NIDDM) as monotherapy with diet and exercise (whose hyperglycaemia cannot be controlled satisfactorily by diet and exercise alone); or in combination with
metform in overweight patients (whose hyperglycaemia cannot be controlled by either repaglinide or metformin alone even in conjunction with diet & exercise).<br><br>
<strong>C/I:</strong> Known hypersensitivity to the drug or its excipients; Type 1 diabetes mellitus; diabetic ketoacidosis, with or without coma; severe renal or hepatic impairment; pregnancy and breast- feeding.<br><br>
<strong>S/E:</strong> Gastrointestinal side-effects include- abdominal pain, diarrhoea, constipation, nausea and vomiting. Hypersensitivity reactions include rashes and urticaria. Other side-effects may include- elevated liver enzymes, paresthesia, chest pain, upper respiratory tract infections, urinary tract infections & tooth disorder.
Precautions & warnings: Use with caution in impaired hepatic function. Safety and efficacy have not been established in children. Substitute insulin during intercurrent illness such as, myocardial infarction, coma, infection, trauma, surgical intervention & renal impairment. All oral blood glucose lowering drugs are capable of producing hypoglycaemia so, repaglinide should be administered with meals to lessen the risk of hypoglycaemia.<br><br>
<strong>Pregnancy & lactation:</strong> Repaglinide is not recommended during pregnancy and lactation, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> Initially 0.5mg to 1mg within 30 minutes before main meals, adjusted according to response at intervals of 1-2 weeks; upto 4mg may be given as a single dose, maximum 16mg daily. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.<br><br> <strong>Drug Inter:</strong> Repaglinide metabolism may be inhibited by antifungal agents like ketoconazole & miconazole, and antibacterial agents like erythromycin, clarithromycin & azithromycin; may be increased by troglitazone, rifampicin, barbiturates & carbamazepine. Highly protein- bound drugs (e.g NSAIDs) may increase the plasma level of unbound repaglinide and potentiate its glucose lowering effect. Thus concurrent administration of these drugs with repaglinide may increase the risk of hypoglycaemia. Concomitant administration with salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase (MAO) inhibitors, and b-adrenergic blockers may increase the risk of hypoglycaemia.   </p>
        </div><!-- collapsible -->
  		
  		


  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAREPA Tab. Techno Drugs</h3>
  		    <p>Repaglinide INN 1mg/tablet. 1mg x 30's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIANORM Tab. Rephco</h3>
  		    <p>Repaglinide INN 1mg/tablet. 1mg x 50's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLIMET Tab. Drug Inter.</h3>
  		    <p>Repaglinide INN 1mg/tablet. 1mg x 50's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLURETOR Tab. Pacific</h3>
  		    <p>Repaglinide INN 0.5mg, 1mg & 2mg/tablet. 0.5mg x 30's pack: 84.00 MRP 1mg x 30's pack: 120.00 MRP 2mg x 30's pack: 180.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NOMOPIL Tab. Incepta</h3>
  		    <p>Repaglinide INN 0.5mg, 1mg & 2mg/tablet. 0.5mg x 100's pack: 200.00 MRP 1mg x 100's pack: 300.00 MRP 2mg x 50's pack: 250.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PRANDIL-1 Tab. UniHealth/UniMed</h3>
  		    <p>Repaglinide INN 1mg/tablet. 1mg x 30's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREFID Tab. White Horse</h3>
  		    <p>Repaglinide INN 1mg & 2mg/tablet. 1mg x 50's pack: 150.00 MRP 2mg x 30's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREMIL Tab. Beximco</h3>
  		    <p>Repaglinide INN 0.5mg, 1mg & 2mg/tablet. 0.5mg x 30's pack: 60.00 IP 1mg x 30's pack: 90.00 IP 2mg x 30's pack: 150.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>REGLIN Tab. General</h3>
  		    <p>Repaglinide INN 0.5mg & 1mg/tablet. 0.5mg x 45's pack: 90.00 MRP 1mg x 30's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>REPAGLID Tab. Alco Pharma</h3>
  		    <p>Repaglinide INN 1mg & 2mg/tablet. 1mg x 30's pack: 90.00 MRP 2mg x 30's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>REPRAN Tab. Square Repaglinide</h3>
  		    <p>INN 0.5mg, 1mg & 2mg/tablet. 0.5mg x 60's pack: 120.00 MRP 1mg x 60's pack: 180.00 MRP 2mg x 50's pack: 250.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>SINGLIN Tab. Renata Repaglinide</h3>
  		    <p>INN 0.5mg, 1mg & 2mg/tablet. 0.5mg x 100's pack: 200.00 MRP 1mg x 100's pack: 300.00 MRP 2mg x 50's pack:250.00 MRP</p>   
  		</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   

    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Thiazolidinedione" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Thiazolidinedione  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> PIOGLITAZONE: Tablet  </h3>
          <p>Pioglitazone is a newer oral antidiabetic agent, belonging to the thiazolidinedione group. It improves insulin sensitivity by decreasing insulin resistance in patients with Type 2 diabetes mellitus. It is available as pioglitazone hydrochloride INN 15mg & 30mg tablet.<br><br>
<strong>Mode of action:</strong> In Type 2 diabetes mellitus (NIDDM), where the cause of diabetes is the development of insulin resistance in the periphery and in the liver- pioglitazone decreases insulin resistance in the peripheral tissues (skeletal muscle & adipose tissue) and in the liver- as it is a potent and highly selective agonist for 'peroxisome proliferator activated receptor gamma (PPARg)', activation of PPARg nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. Thus, pioglitazone improves insulin sensitivity in muscles and adipose tissues and inhibits hepatic gluconeogenesis.<br><br>
<strong>Ind:</strong> Pioglitazone is indicated in patients with Type 2 diabetes mellitus (NIDDM) as an adjunct to diet & exercise to bring glycaemic control. It may be used alone or in conjunction with insulin, metformin (in obese patients), or a sulfonylurea when diet & exercise plus the single agent does not bring satisfactory glycaemic control.<br><br>
<strong>C/I:</strong> Pioglitazone is contraindicated in liver disease, heart disease; Type 1 diabetes mellitus (insulin-dependent diabetes) and diabetic ketoacidosis. It should not be given to patients who have a serious infection, illness, injury or need surgery. Known hypersensitivity to this product or any of its components.<br><br>
<strong>S/E:</strong> More common- problem with tooth, headache, cough, fever, myalgia, sore throat, stuffy nose and sinusitis. Less common- anaemia, oedema & swelling of feet or lower legs. <br><br>Warnings & pre<strong>Cautions:</strong> Use cautiously in patients with oedema. If a patient misses a dose, he has to take the missed dose as soon as he remembers. If he does not remember until the next day, should skip the dose he missed and take only his next regularly scheduled dose but should not take double dose. Follow the diet, medication and exercise routines very closely. Use carefully with other drugs and during taking alcohol. Hyperglycaemia may occur if one does not take adequate or skip a dose of drug.<br><br>
<strong>Pregnancy & lactation:</strong> Pioglitazone is not recommended during pregnancy and lactation, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> The dose of pioglitazone will be different in different conditions. Pioglitazone alone: Adults- at first, the dose is 15 or 30mg once daily; it may be increased later up to 45mg once daily. Children- dose must be determined by the physician. Pioglitazone with insulin, metformin or sulfonylurea: Adults & children- dose is as smae as pioglitazone alone. Pioglitazone may be taken with or without food by a full glass of water.
<br><br><strong>Drug Inter:</strong> Use of ketoconazole with pioglitazone may decrease the effect of pioglitazone. Pioglitazone may reduce the effect of some birth control pills.    </p>
        </div><!-- collapsible -->
  		


  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ACTOSE Tab. UniMed & UniHealth</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.15mg x 30's pack: 240.00 MRP 30mg x 20's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ADPAS Tab. General</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg/tablet. 15mg x 30's pack: 240.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAGLIT Tab. Beximco</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.15mg x 30's pack: 240.00 IP 30mg x 30's pack: 450.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DIAPIOTAB Tab. Medimet</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.15mg x 50's pack: 400.00 MRP 30mg x 50's pack: 600.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLITAZON Tab. Ibn Sina</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg/tablet. 15mg x 30's pack: 180.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>GLUCOZON Tab. Aristopharma</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.
  		15mg x 30's pack: 210.00 MRP 30mg x 20's pack: 220.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>LIT Tab. White Horse</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.15mg x 50's pack: 350.00 MRP 30mg x 50's pack: 460.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>OGLI-30 Tab. Chemico</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg/tablet. 30mg x 20's pack: 240.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PEEGEE Tab. Jayson</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.15mg x 30's pack: 180.00 IP 30mg x 30's pack: 300.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PIGLIT Tab. Pacific</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.15mg x 30's pack: 240.00 MRP 30mg x 30's pack: 360.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PIODAR Tab. Incepta</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.
  		15mg x 30's pack: 240.00 MRP 30mg x 20's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PIOGLIN Tab. Renata</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet (film coated). 15mg x 30's pack: 240.00 MRP 30mg x 10's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PIOL Tab. Opsonin</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg/tablet (f.c). 15mg x 30's pack: 240.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PIOLIT Tab. Alco Pharma</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg/tablet. 15mg x 30's pack: 240.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>POIZENA Tab. Drug Inter.</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.
  		15mg x 50's pack: 300.00 MRP 30mg x 30's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>TOS Tab. Square</h3>
  		    <p>Pioglitazone hydrochloride INN 15mg & 30mg/tablet.
  		15mg x 30's pack: 240.00 MRP 30mg x 30's pack: 360.00 MRP</p>   
  		</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="ROSIGLITAZONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> ROSIGLITAZONE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" 
      title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" 
      title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ROSIGLITAZONE: Tablet </h3>
          <p>  Rosiglitazone is a newer oral antidiabetic agent, belonging to the thiazolidinedione group. It improves insulin sensitivity by decreasing insulin resistance in patients with Type 2 diabetes mellitus. It is available as rosiglitazone maleate INN 2mg & 4mg tablet.<br><br>
<strong>Mode of action:</strong> See above under the text of pioglitazone.<br><br>
<strong>Ind:</strong> 1. Rosiglitazone is indicated as monotherapy as an adjunct to diet & exercise to improve glycemic control in type-2 diabates.
2. In combination with a sulfonylurea, repaglinide, metformin, acarbose, or insulin when diet, exercise and single agent do not result in adequate glycemic control.
3. In combination with- i. Sulfonylurea or repaglinide plus metformin ii. Sulfonylurea or repaglinide plus acarbose iii. Sulfonylurea or
repaglinide plus insulin, when diet, exercise & 2- drug regimen do not result in adequate glycemic control.<br><br>
<strong>C/I:</strong> See above under the text of pioglitazone. <br><br><strong>S/E:</strong> Gastrointestinal disturbances, headache, dizziness, edema, anemia, & weight gain occur which are usually mild to moderate in severity & generally do not require discontinuation of treatment with rosiglitazone.
Precaution: See above under the text of pioglitazone. Monitoring of liver functions before treatment should be done in all patients & periodically thereafter.<br><br>
<strong>Pregnancy & lactation:</strong> Rosiglitazone is not recommended during pregnancy and lactation, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> The management of antidiabetic therapy should be individualized. Monotherapy: Rosiglitazone may be administered either at a starting dose of 4mg as a single daily dose or divided as 2mg twice daily in the morning and evening. For patients who respond inadequately following 8-12 weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to maximum of 8mg daily as a single dose or divided (twice daily) as monotherapy; or may be given in combination with any other insulin secretor or sensitizer or insulin, or any other 2-drug (antidiabetic) regimen. Rosiglitazone may be taken with or without food.
Combination therapy: When rosiglitazone is added to exiting therapy, the current dose of the agent can be continued upon initiation of rosiglitazone therapy.
Sulfonylurea: When used in combination with sulfonylurea, rosiglitazone may be administered either at a starting dose of 4mg as a single daily dose or divided as 2mg twice daily. While giving with an insulin secretagogue, the dose of sulfonylurea should be decreased if patients report hyperglycemia. Metformin: When used in combination with metformin, rosiglitazone may be administered either at a starting dose of 4mg as a single daily dose or divided as 2mg twice daily. It is unlikely that the dose of metformin will require adjustment due to hypoglycemia during combination therapy with rosiglitazone. Insulin: Dose of rosiglitazone greater than 4mg daily in combination with insulin are not currently indicated. It is rcommended that the insulin dose be decreased by 10-25% if the patients report hypoglycemia or if FPG concentration decrease to less than 100mg/dl. Further adjustments should be individualized based on glucose-lowering response.
No dosage adjusment is required when rosiglitazone is used as monotherapy in patients with renal impairment.
Use in children: The safety & effectiveness of rosiglitazone in pediatric patients under 18
years have not been established.<br><br>
<strong>Drug Inter:</strong> A decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced. Dosage adjustment is also required when administered with rifampicin. It was shown to have no clinically relevant effect on the pharm- acokinetics of nifedipine & oral contraceptives.  </p>
        </div><!-- collapsible -->
  		
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ROGLIT 4 Tab. Pacific</h3>
            <p>Rosiglitazone maleate INN 4mg/tablet (f.c). 4mg x 30's pack: 240.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ROMEROL Tab. Drug Inter.</h3>
            <p>Rosiglitazone maleate INN 2mg & 4mg/tablet (f.c) 2mg x 50's pack: 250.00 MRP
        4mg x 30's pack: 240.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ROSIT Tab. Delta</h3>
            <p>Rosiglitazone maleate INN 2mg & 4mg/tablet (f.c). 2mg x 30's pack: 150.00 MRP
        4mg x 30's pack: 270.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>SENSULIN Tab. Square Rosiglitazone</h3>
            <p>maleate INN 2mg & 4mg/tablet (f.c). 2mg x 30's pack: 150.00 MRP 4mg x 30's pack: 240.00 MRP</p>   
        </div><!-- collapsible -->



      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Combination preparations" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Combination preparations </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

      	
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> GLIMEPIRIDE + ROSIGLITAZONE  </h3>
          <p>  This is a combination of two antihyperglycemic agents, in which glimepiride is a member of second generation sulfonylurea and rosiglitazone maleate is a member of the thiazolidinedione group of other antidiabetics.
The combination preparations of glimepiride and rosiglitazone are available in two fixed presentations viz: i. Glimepiride 1mg + rosiglitazone 4mg; ii. Glimepiride 2mg + rosiglitazone 4mg<br><br>
<strong>Mode of action:</strong> See above under the text of glimepiride & rosiglitazone given separately. <br><br><strong>Ind:</strong> This combination is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of rosiglitazone and sulfonylurea as separate tablet or who are not adequately controlled on a sulfonylurea alone or for those patients who have initially responded to rosiglitazone alone and require additional glycemic control.<br><br>
<strong>C/I:</strong> Combination of glimepiride and rosiglitazone is contraindicated in patients with:
i. Known hypersensitivity to any of the
components of the combination.
ii. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.<br><br> Pre<strong>Cautions:</strong> General: Rosiglitazone or rosiglitazone containing combination therapy should not be used in patients with type 1 diabetes
(absence of endogenous insulin) or for the
treatment of diabetic ketoacidosis. Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Therefore, proper patient selection, dosage and instruction are important to avoid hypoglycemic episodes. Elderly patients are particulary susceptible to hypoglycemic action of glucose lowring drugs. Edema & Heart failure: Combination of glimepiride and rosiglitazone should be used with caution in patients with edema. Since thiazolidinediones, including rosiglitazone can cause fluid retention, which can exacerbate or lead to congestive heart failure. So, combination of glimepiride and rosiglitazone should be used with caution in patients at risk for heart failure. Hepatic effects: Liver enzymes should be checked prior to the initiation of therapy with combination of glimepiride and rosiglitazone in all patients and periodically thereafter for the clinical judgement of the healthcare professional. Therapy with combination of glimepiride and rosiglitazone should not be initiated in patietns with increased baseline liver enzyme levels (ALT>2.5 x upper limit of normal). If at any time ALT levels increase to >3 x the upper limit of normal in patients on therapy with combination of glimepiride and rosiglitazone, liver enzyme levels should be rechecked as soon as possible. If ALT levels remain >3 x the upper limit of normal, therapy with combination of glimepiride and rosiglitazone should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, and anorexia, and/or dark urine, liver enzymes should be checked.<br><br>
<strong>Pregnancy & lactation:</strong> This combination is not recommended during pregnancy & lactation, so, a suitable treatment schedule should be prescribed with insulin.
Dogage & admin: This combined preparation should be given once daily with the first meal of the day. The dosage of antidiabetic therapy with this combination should be individualized on the basis of effectiveness and tolerability. For patients inadequately controlled on sulfonylurea monotherapy or who have initially responded to rosiglitazone alone and require additional glycemic control, the usual starting dose of glimepiride and rosiglitazone combination is 1mg/4mg or 2mg/4mg once daily. When switching from combination therapy of glimepiride and rosiglitazone as separate tablets, the usual starting dose is the dose of glimepiride and rosiglitazone already being taken. The maximum recommended daily dose of this combination is 4mg of glimepiride and 8mg of rosiglitazone. Sufficient time should be given to assess adequacy of therapeutic response. Fasting glucose should be used to determine the therapeutic response to this combination therapy. For patients previously treated with sulfonylurea monotherapy switched to this combination- it may take 2 weeks to see a reduction in blood glucose and 2 to 3 months to see the full effect of the rosiglitazone component. If additional glycemic control is needed, the dose of the glimepiride component may be increased. The dose of the rosiglitazone component should not exceed 8mg. As with other sulfonylurea- containing antidiabetic agents, no transition period is necessary when transferring patients to this combination therapy. Patients should be observed carefully (1 to 2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g chlorpropamide) to this combination therapy due to potential overlapping of drug effect. For patients previously treated with thiazolidinedione monotherapy switched to this combination therapy, dose titration is recommended if patients are not adequately controlled after 1 to 2 weeks. If additional glycemic control is needed, the daily dose of this combination may be increased by increasing the glimepiride component in no more than 2mg increments at 1 to 2 weeks intervals up to the maximum recommended total daily dose of 4mg glimepiride/8mg rosiglitazone. If hypoglycemia occurs during up-titration of the dose or while maintained on therapy, a dosage reduction of the sulfonylurea component of this combination may be considered.  </p>
        </div><!-- collapsible -->


        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLYROS 1 Tab. Square</h3>
            <p>Glimepiride 1mg + rosiglitazone 4mg/tablet 30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLYROS 2 Tab. Square</h3>
            <p>Glimepiride 2mg + rosiglitazone 4mg/tablet 30's pack: 330.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>SUGANA 1 Tab. Pacific</h3>
            <p>Glimepiride 1mg + rosiglitazone 4mg/tablet 30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>SUGANA 2 Tab. Pacific</h3>
            <p>Glimepiride 2mg + rosiglitazone 4mg/tablet 30's pack: 360.00 MRP</p>   
        </div><!-- collapsible -->


      </div><!-- collapsible-set -->

	


    <div data-role="collapsible-set" data-theme="e">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> GLIPIZIDE + METFORMIN </h3>
          <p>  This is a combination of two antihyperglycemic agents, in which glipizide is a sulfonylurea and metformin is a biguanide.
The combination preparations of glipizide and metformin are available in three fixed presentations, viz: i. Glipizide 2.5mg + Metformin hydrochloride 250mg, ii. Glipizide 2.5mg + Metformin hydrochloride 500mg, and iii. Glipizide 5mg + Metformin hydrochloride 500mg. <br><br><strong>Mode of action:</strong> See above under the text of glipizide & metformin given separately.<br><br>
<strong>Ind:</strong> This combination is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone. It is also indicated as second line therapy when diet, exercise and initial treatment with glipizide or metformin do not result in adequate glycemic control in patients with type 2 diabetes.<br><br> <strong>C/I:</strong> Severe hepatic or renal dysfunction; congestive heart failure requiring pharmacologic treatment; known hypersensitivity to glipizide or metformin hydrochloride; acute or chornic metabolic acidosis, including diabetic acidosis, with or without coma. <br><br><strong>S/E:</strong> The most common side effects of this combination are normally minor ones such as diarrhea, nausea, vomiting, dizziness, headache and abdominal pain which usually occur during the first few weeks of therapy.<br><br>
Pre<strong>Cautions:</strong> In the events of severe trauma, injuries, infectious diseases, severe renal & hepatic impairment, myocardial infarction, coma, high fever & surgery it may be necessary to give insulin to maintain adequate metabolic control. Patients receiving continuous therapy should have an annual estimation of vitamin B12 level. <br><br><strong>Pregnancy & lactation:</strong> This combination is not recommended during pregnancy & lactation, so, a suitable treatment schedule should be prescribed with insulin.
<br><br><strong>Dosage & admin:</strong> Initial therapy: For patients with type 2 diabetes whose hyperglycemia can not be satisfactorily managed with diet and exercise alone: the recommended starting dose of combination is 2.5mg/250mg once daily with meal. In clinical trials of this combination as initial therapy, there was no experience with total daily doses greater than 10mg/2000mg per day. Second line therapy: For patients not adequately controlled on either glipizide or metformin alone, the recommended starting dose of this combination is 2.5mg/500mg or 5mg/500mg twice daily with the morning and evening meals. The daily dose should be titrated in increments of no more than 5mg/500mg up to the minimum effective dose to achieve adequate control of blood glucose or to a maximum dose of 20mg/2000mg per day. <br><br><strong>Drug Inter:</strong> The hypoglycemic action of glipizide component may be potentiated by aspirin & phenylbutazone, sulfonamides, chloramphenicol, coumarins, probenecid, monoamino oxidase inhibitors, beta-adrenergic blocking agents, H2 antagonists and oral antifungal agents like miconazole and fluconazole. Metformin may enhance the effects of anticoagulants, thiazides, corticosteroids, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid tend to produce hyperglycemia and may lead to loss of glycemic control.  </p>
        </div><!-- collapsible -->
      


        <div data-role="collapsible"> <!-- collapsible -->
            <h3>COMBIMET Tab. Beximco</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 250mg/tablet (f.c).
        100's pack: 180.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>COMBIMET Plus Tab. Beximco</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 500mg/tablet (f.c).
        60's pack: 120.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>COMBIMET DS Tab. Beximco</h3>
            <p>Glipizide 5mg + metformin hydrochloride 500mg/tablet (f.c).
        60's pack: 168.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLUMIN Tab. Apex</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 250mg/tablet (f.c).50's pack: 80.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLUMIN Plus Tab. Apex</h3>
            <p>Glipizide 5mg + metformin hydrochloride 500mg/tablet (f.c).
        50's pack: 140.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLYMIN Plus Tab. Healthcare</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 500mg/tablet (Lc).
        30's pack: 97.50 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MEFOGLIP 250 Tab. Incepta</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 250mg/tablet (f.c).
        50's pack: 95.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MEFOGLIP 500 Tab. Incepta</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 500mg/tablet (f.c). 30's pack: 84.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MEFOGLIP DS Tab. Incepta</h3>
            <p>Glipizide 5mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 111.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>METAZID Tab. Popular</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 75.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>METGLIP Tab. Pacific</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 250mg/tablet (f.c).
        50's pack: 95.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>METGLIP Plus Tab. Pacific</h3>
            <p>Glipizide 2.5mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 89.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>METGLIP DS Tab. Pacific</h3>
            <p>Glipizide 5mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 120.00 MRP</p>   
        </div><!-- collapsible -->


      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  PIOGLITAZONE + METFORMIN </h3>
          <p>  This is a combination of two antihyperglycemic agents, in which metformin is a biguanide and pioglitazone is a member of the thiazolidinedione group of other antidiabetics.
The combination preparations of pioglitazone and metformin are available as tablet in two fixed presentations, viz: i. Pioglitazone 15mg + Metformin hydrochloride BP 500mg; ii. Pioglitazone 15mg + Metformin hydrochloride BP 850mg.<br><br>
<strong>Mode of action:</strong> See above under the text of pioglitazone and metformin given separately. <br><br><strong>Ind:</strong> This combination is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes- i. who are already treated with a combination of pioglitazone and metformin as separate tablets, or ii. whose diabetes is not adequately controlled with metformin alone, or iii. for those patients who have initially responded to pioglitazone alone and require additional glycemic control.
<br><br><strong>C/I:</strong> Combination of pioglitazone and metformin is contraindicated in patients with: i. Renal disease or renal dysfunction [e.g, as suggested by serum creatinine levels >1.5mg/dl (males), > 1.4mg/dl (females), or abnormal creatinine clearance] which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia; ii. Known
hypersensitivity to pioglitazone, metformin or any other component of the combination; iii. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin. Combination of pioglitazone and metformin should be temoprarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, becaues use of such products may result in acute alteration of renal function.<br><br>
<strong>S/E:</strong> The most common adverse events were upper respiratory tract infection, diarrhea, combined edema/peripheral edema and headache, respectively. Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy.<br><br>
Pre<strong>Cautions:</strong> General: Pioglitazone hydrochloride exerts its antihyperglycemic effect only in the presence of insulin. Therefore, combination of pioglitazone and metformin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Metformin is known to be substantially excreted by the kidney and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive combination of pioglitazone & metformin. Cardiovascular: Therapy with pioglitazone, cases of congestive heart failure has been reported in patients both with and without previously known heart disease. Edema & heart failure: Combination of pioglitazone and metformin should be used with caution in patients with edema. Since thiazolidinediones, including pioglitazone can cause fluid retention, which can exacerbate or lead to congestive heart failure. So, combination of pioglitazone and metformin should be used with caution in patients at risk for heart failure.
Hepatic effects: Serum ALT (alanine aminotransferase) levels should be evaluated prior to the initiation of therapy with combination of pioglitazone and metformin in all patients and periodically thereafter do the clinical judgment of the health care professional. Other liver function tests should also be done for patients if symptoms suggestive of hepatic dysfunction, e.g nausea, vomiting, abdominal pain, fatigue, anorexia, or dark urine. If jaundice is observed, drug therapy should be discontinued.<br><br>
<strong>Pregnancy & lactation:</strong> This combination is not recommended during pregnancy & lactation, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> Selecting the starting dose of this combination should be based on the patient's current regimen of pioglitazone and/or metformin. This combination should be given in divided daily doses with meals to reduce the gastrointestinal side effects associated with metformin.
Starting dose for patients inadequately controlled on metformin monotherapy: Based on the usual starting dose of pioglitazone (15-30mg daily), this combination may be initiated at either the 15mg/500mg or 15mg/850mg tablet once or twice daily, and gradually titrated after assessing adequacy of therapeutic response. Starting dose for patients who initially responded to pioglitazone monotherapy and require additional glycemic control: Based on the usual starting doses of metformin (500mg twice daily or 850mg daily), this combination may be initiated at either the 15mg/500mg tablet twice daily or 15mg/850mg tablet once daily, and gradually titrated after assessing adequacy of therapeutic response.
Starting dose for patients switching from combination therapy of pioglitazone plus metformin as separate tablets: Either combination 15mg/500mg or combination 15mg/850mg based on the dosage of pioglitazone and metformin already being taken.
Maximum recommended dose: The maximum recommended dose for pioglitazone is 45mg daily. The maximum recommended daily dose for metformin is 2550mg in adults.  </p>
        </div><!-- collapsible -->


        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ACTOMEG 500 Tab. UniMed Pharma</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 500mg/tablet (f.c).
        20's pack: 180.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PACTOMEG 850 Tab. UniMed Pharma</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 850mg/tablet (f.c).
        20's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>COMPIMET 500 Tab. Incepta</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 270.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>COMPIMET 850 Tab. Incepta</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 850mg/tablet (f.c).30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLITAMIN 500 Tab. White Horse</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 270.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLITAMIN 850 Tab. White Horse</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 850mg/tablet (f.c).
        30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PIOMET 500 Tab. Silva</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 180.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PIOMET 850 Tab. Silva</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 850mg/tablet (f.c).
        30's pack: 210.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PIOMIN 500 Tab. Pacific</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 500mg/tablet (f.c).30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PIOMIN 850 Tab. Pacific</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 850mg/tablet (f.c).
        30's pack: 345.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>REZULIN 500 Tab. Square</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 500mg/tablet (f.c).
        30's pack: 270.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>REZULIN 850 Tab. Square</h3>
            <p>Pioglitazone 15mg + metformin hydrochloride 850mg/tablet (f.c).30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->


	


        <div data-role="collapsible-set" data-theme="e">

          <div data-role="collapsible"> <!-- collapsible -->
            <h3>  ROSIGLITAZONE + METFORMIN </h3>
            <p> This is a combination of two antihyperglycemic agents, in which metformin is a biguanide and rosiglitazone is a member of the thiazolidinedione group of other antidiabetics.
The combination preparations of rosiglitazone and metformin are available as tablet in two fixed presentations, viz: i. Rosiglitazone 1mg + Metformin hydrochloride BP 500mg; ii. Rosiglitazone 2mg + Metformin hydrochloride BP 500mg.<br><br>
<strong>Mode of action:</strong> See above under the text of rosiglitazone and metformin given separately. <br><br><strong>Ind:</strong> This combination is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes- i. who are already treated with a combination of rosiglitazone and metformin as separate tablets, or ii. whose diabetes is not adequately controlled with metformin alone, or iii. for those patients who have initially responded to rosiglitazone alone and require additional glycemic control.
<br><br>C/I; S/E; Pre<strong>Cautions:</strong> See above under the text of pioglitazone & metformin combined preparations.<br><br> <strong>Pregnancy & lactation:</strong> This combination is not recommended during pregnancy & lactation, so, a suitable treatment schedule should be prescribed with insulin.<br><br>
<strong>Dosage & admin:</strong> General: The dosage of antidiabetic therapy with this combination should be individualized on the basis of the effectiveness and tolerability of the individual component of the product. All patients should start the rosiglitazone component of the combination at the lowest recommended dose. Further increases in the dose of rosiglitazone should be accompanied by careful monitoring for adverse events related to fluid retention. This combined preparation is generally given
in divided doses with meals, with gradual dose escalation. This reduces gastrointestinal side effects (largely due to metformin) and permits determination of the minimum effective dose for the individual patient.
Combination therapy in drug-native patients: The recommended starting dose of this combination is 2mg/500mg administered once or twice daily. For patients with HbA 1c>11% or FPG>270mg/dl, a starting dose of 2mg/500mg twice daily may be considered. The dose of this combination may be increased in increments of 2mg/500mg per day to a maximum of 8mg/2,000mg per day given in divided doses if patients are not adequately controlled after 4 weeks.
Combination therapy in patients inadequately controlled with rosiglitazone or metformin monotherapy: The selection of the dose of this combination in patients treated with rosiglitazone and/or metformin therapy should be based on the patient's current doses of rosiglitazone and/or metformin. After an increase in metformin dosage, dose titration is recommended if patients are not adequately controlled after 1 to 2 weeks. After an increase in rosiglitazone dosage, dose titration is recommended if patients are not adequately controlled after 8 to 12 weeks.
For patients inadequately controlled on metformin monotherapy, the usual starting dose of this combination is 4mg rosiglitazone (total daily dose) plus the dose of metformin already being taken.
For patients inadequately controlled on rosiglitazone monotherapy, the usual starting dose of this combination is 1000mg metformin (total daily dose) plus the dose of rosiglitazone already being taken.
When switching from combination therapy of rosiglitazone plus metformin as separate tablets, the usual starting dose of this combination is the dose of rosiglitazone & metformin already being taken.   </p>
          </div><!-- collapsible -->
        


          <div data-role="collapsible"> <!-- collapsible -->
              <h3>METIGLIT 1 Tab. General</h3>
              <p>Rosiglitazone 1mg + metformin hydrochloride 500mg/tablet (f.c).
          30's pack: 120.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>METIGLIT 2 Tab. General</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 500mg/tablet (f.c).30's pack: 180.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>ORAMET-PLUS Tab. Drug Inter.</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 500mg/tablet (f.c).
          50's pack: 350.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>ROGMET 2 Tab. Pacific</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 500mg/tablet (f.c).
          30's pack: 180.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>ROSIMET 1 Tab. Delta</h3>
              <p>Rosiglitazone 1mg + metformin hydrochloride 500mg/tablet (f.c).
          30's pack: 180.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>ROSIMET 2 Tab. Delta</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 500mg/tablet (f.c).30's pack: 240.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>ROSIMIN 1 Tab. White Horse</h3>
              <p>Rosiglitazone 1mg + metformin hydrochloride 500mg/tablet (f.c).
          50's pack: 200.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>ROSIMIN 2 Tab. White Horse</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 500mg/tablet (f.c).
          50's pack: 300.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>SENSIMET 1 Tab. Square</h3>
              <p>Rosiglitazone 1mg + metformin hydrochloride 500mg/tablet (f.c).
          30's pack: 120.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>SENSIMET 1 DS Tab. Square</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 1000mg/tablet (f.c).
          30's pack: 225.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>SENSIMET 2 Tab. Square</h3>
              <p>Rosiglitazone 2mg + metformin hydrochloride 500mg/tablet (f.c).30's pack: 180.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>SENSIMET 2 DS Tab. Square</h3>
              <p>Rosiglitazone 4mg + metformin hydrochloride 1000mg/tablet (f.c).
          30's pack: 300.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>SENSIMET 4 Tab. Square</h3>
              <p>Rosiglitazone 4mg + metformin hydrochloride 500mg/tablet (f.c).30's pack: 255.00 MRP</p>   
          </div><!-- collapsible -->
        </div><!-- collapsible-set -->
      
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="THYROID" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> THYROID & ANTITHYROID DRUGS   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 


<a href="#" data-role="button" data-theme="a"> Thyroid drugs & Hormones </a>
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> THYROXINE/LEVOTHYROXINE  </h3>
          <p>  Thyroxine sodium (levothyroxine sodium) is a synthetic thyroid hormone, used in the thyroxine replacement therapy. Thyroxine (T4) is a naturally occurring hormone produced by the thyroid gland & converted to the more active hormone tri- iodothyronine (T3) in peripheral tissues. The thyroid hormones are required for normal growth and development particularly of the nervous system. Thyroxine sodium (levothyroxine sodium) after ingestion is incompletely and variably absorbed from the gastrointestinal tract. The half- life of T4 in normal plasma is 6-7 days, while that of T3 is about 1 day. The plasma half-lives
of T4 and T3 are decreased in hyperthyroidism and increased in hypothyroidism. Thyroxine sodium (Levothyroxine sodium) is largely bound to plasma protein, mainly to thyroxine binding globulin (TBG) but also to prealbumin and less avidly to albumin. The unbound or free fraction, although only about 0.03% of total thyroxine sodium (levothyroxine sodium), is of course the fraction available for peripheral action and conversion to the more active metabolite tri- iodothyronine (T3).<br><br>
<strong>Ind:</strong> 1. Congenital hypothyroidism including cretinism 2. Acquired hypothyroidism- primary thyroid failure, autoimmune, post surgery, post radioiodine therapy, drug therapy, myxoedema 3. Hypothyroidism secondary to pituitary/
hypothalamic diseases 4. Suppression of goiter 5. In conjunction with antithyroid drugs in treatment of thyrotoxicosis.<br><br>
<strong>C/I:</strong> Thyroxine sodium (levothyroxine sodium) is contraindicated in patients with thyrotoxicosis, angina, cardiovascular disorders; hypersensitivity to thyroid hormone. It is also contraindicate_
the patients with uncorrected adrenal
insufficiency.<br><br>
<strong>S/E:</strong> Side-effects may include anginal pain, arrhythmias, palpitation, skeletal muscle cramps, tachycardia, diarrhoea, vomiting, tremors, restlessness, excitability, insomnia, headache, flushing, sweating, fever, heat intolerance, excessive loss of weight and muscular weakness. <br><br>Pre<strong>Cautions:</strong> Thyroxine sodium (levothyroxine sodium) should be used with caution in patients with cardiovascular disorders, including angina, coronary artery disease, and hypertension, and in the elderly who have a greater likelihood of occult cardiac disease. Use of thyroxine sodium (levothyroxine sodium) in patients with concomitant diabetes mellitus, diabetes insipidus or adrenal cortical insufficiency may aggravate the intensity of their symptoms. Appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases may therefore be required.<br><br>
<strong>Pregnancy & lactation:</strong> Women on maintenance levothyroxine for hypothyroidism who become pregnant should not need to alter the dose because of the pregnancy so long as they are confirmed to be euthyroid initially, by normal TSH levels. T4 dose not cross the placental barrier in the second and third trimester, although it may do so in early pregnancy. The amount of T4 in breast milk is variable but not sufficient to affect the normal infant.<br><br>
<strong>Dosage & admin:</strong> In adult patients without cardac problems: initially adult oral dose is 50- 100mcg daily, preferably in the fasting state, adjusted in steps of 50mcg every 3-4 weeks until normal metabolism maintained. The patient's well being and thyroid function tests are reassessed after 6-8 weeks. The daily dosage may then require further minor adjustment so as to ensure clinical and biochemial euthyroidism. It is important to correct any steroid deficiency first before initiating thyroxine replacement therapy.
In the elderly & in patients with cardiac problems: Initially 25mcg daily or 50mcg on alternate days adjusted in steps of 25mcg every 4 weeks until euthyroid.
Maintenance therapy: The usual maintenance dose to relieve hypothyro-idism is 100-200mcg daily, which can be administered as a single dose.
Neonates & children: Replacement therapy should be started as soon as the diagnosis is made to prevent the mental and physical retardation that would otherwise occur. The initial diagnosis and cause can be reappraised when the infant is 1 year old.
Dosage: At age 0-6 mon, 8-10mcg/kg/day; 6-12mon, 6-8mcg/kg/day; 1-5 yrs; 5- 6mcg/kg/day; 6-12 yrs; 4-5mcg; 12 years and over 2mcg/kg/day.
Over dosage: A massive acute overdose is fortunately uncommon, but potentially lethal. If
the patient presents soon after ingestion of an acute overdose then gastric aspiration and lavage are indicated. Other treatment includes propranolol and supportive measures to maintain the circulation.<br><br>
<strong>Drug Inter:</strong> Levothyroxine, when given to hypothyroid patients who are already on anticoagulants, will potentiate the effect of warfarin and other dicoumarin anticoagulants necessitating a marked reduction (50%) in warfarin dosage to prevent execessive prolongation of the prothrombin time and partial thrombo-plastin time.
Cholestyramine may reduce absorption of levothyroxine. Phenylbutazone, carbamazepine and phenytoin may cause a false low total serum T4 levels. Serum T3 and TSH levels rather than T4 should be used to monitor the patient's thyroid status.  </p>
        </div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>EUTHYCIN Tab. Incepta</h3>
  		    <p>Levothyroxine sodium 50mcg/tablet 100's pack: 120.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>OROXINE Tab. GlaxoSmithKline</h3>
  		    <p>Thyroxine sodium 50mcg/tablet 200's pack: 442.25 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>THYROX Tab. Renata</h3>
  		    <p>Thyroxine sodium 50mcg/tablet 90's pack: 108.00 MRP</p>   
  		</div><!-- collapsible -->

      </div><!-- collapsible-set -->



<a href="#" data-role="button" data-theme="a"> Antithyroid drugs </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CARBIIVIAZOLE  </h3>
          <p>   Carbimazole is available as carbimazole BP 5mg/tablet.<br><br>
<strong>Ind:</strong> Thyrotoxicosis.<br><br>
<strong>C/I:</strong> Tracheal obstruction, breast feeding.<br><br>
<strong>S/E:</strong> Nausea, headache, rashes, arthralgia, rarely alopecia, agranulocytosis. Advice patients to inform you of sore throats, mouth ulcer; if so, dicontinue drug.
<br><br><strong>Cautions:</strong> Pregnancy.
<br><br><strong>Pregnancy & lactation:</strong> Carbimazole is contraindicated in breast feeding mother. In pregnant woman it can only be given if it is clearly needed, but caution should be exercised.<br><br>
<strong>Dosage & admin:</strong> Adult: Moderate cases, 30 mg; severe cases, 40-60mg. All daily in divided doses for 4-6 weeks; when the evidence of hyperthyroidism has disappeared, reduce to min. daily dose of 10-15mg to maintain control (treatment is usually maintained for 18 months).
Child: 15 mg daily in divided doses. Preparations: May be available in the market later on. </p>
        </div><!-- collapsible -->
      

      </div><!-- collapsible-set -->



<a href="#" data-role="button"  data-theme="a"> Drugs for Iodine deficiency goitre </a>
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> I-CAP Soft Cap. Drug Inter.  </h3>
          <p>  Iodised oil BP equivalent to iodine BP 200mg/capsule (soft gelatin).
<br><br><strong>Ind:</strong> Iodised oil (iodine) is indicated for the prevention and treatment of iodine deficiency disorders (IDD) which include endemic goitre, endemic cretinism, impaired mental function in children and adults, abortion, retardation of brain development in the fetus and an increased incidence of still births as well as perinatal & infant mortality.<br><br>
<strong>C/I:</strong> Iodised oil (iodine) is contra-indicated in patients with hyperthyroidism & patients who have known hypersensitivity to any component of the product.
<br><br><strong>S/E:</strong> Adverse-effect after taking iodised oil for a short time is rare. But excessive intake of iodised oil can cause goitre, hypothyroidism as well as hyperthyroidism. Other adverse-effects reported with prolonged administration are- iodism, metallic taste, increased salivation, burning or abdominal pain, swelling & inflammation of the throat, pulmonary oedema, skin reaction, gastrointestianl upsets, diarrhea, hyotensison, tachycardia etc.<br><br>
Pre<strong>Cautions:</strong> Iodised oil should be used with care in patients with thyroid dysfunction or with a history of allergic reactions.<br><br>
<strong>Pregnancy & lactation:</strong> It should not be taken regularly during pregnancy or lactation except when iodine supplimentation is required.<br><br>
<strong>Dosage & admin:</strong> Usual oral dose of iodised oil for the prevention and treatment of IDD for 1 year protection is as following:
Infants below 1 year: 1 capsule (200mg) a year. Children over 1 year, adults, pregnant women & nursing mothers: 2 capsules (200mg x 2) every year or as directed by the physician. Elderly patients: Reduced dose should be given to patients over 45 years with nodular goitres. 50's pack: 450.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  LUGOLS IODINE </h3>
          <p>  Aqueous iodine solution (iodine 5%, potassium iodide 10%, made upto 100 parts in purified water), total iodine 130mg/ml.<br><br>
<strong>Ind:</strong> Pre-operative treatment of thyrotoxicosis <br><br><strong>S/E:</strong> Hypersensitivity like reactions, including headache, lachrymation, conjunctivitis, pain in salivary glands, laryngitis, bronchitis, rashes; on prolonged treatment depression, insomnia, impotence, myxoedema; goitre in infants of mothers taking iodides.<br><br>
<strong>Cautions:</strong> Pregnancy, children
Dose: 0.1-0.3 ml 3 times daily (well diluted with milk or water) for about 2 weeks.
Prepn: May be available.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  POTASSIUM IODIDE </h3>
          <p>  Potassium iodide 60mg/tablet <br><br><strong>Ind:</strong> Preoperative treatment of thyrotoxicosis. <br><br>S/E; <strong>Cautions:</strong> Same as Lugol's iodine solution Dose: 30-60mg daily for about 2 weeks. Prepn: May be available. </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="BETAMETHASONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> BETAMETHASONE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  BETAMETHASONE </h3>
          <p>  <strong>Ind:</strong> Severe asthma, hayfever, allergic skin conditions, rheumatoid arthritis, collagen diseases, shock and adrenal crisis.<br><br>
<strong>C/I:</strong> Tuberculosis, local or systemic infections unless controlled by chemotheraphy, herpes simplex keratitis, active peptic ulcer, psychoses, osteoporosis, renal dysfunctions, diabetes mellitus, glaucoma, hypertension, cushing's syndrome, myasthenia gravis, thromboembolic disorders, congestive heart failure, diverticulitis, fresh intestinal anastomoses and pregnancy. <br><br><strong>S/E:</strong> Hypertension, sodium retention, potassium loss, muscle weakness; diabetes; osteoporosis (particularly in elderly); mental disturbances; euphoria is frequently observed; peptic ulceration which may result in haemorrhage or perforation; suppression of growth (in children); spread of infections; adrenal suppression; menstrual irregularities. Overdoses may cause cushing's syndrome, with moon face striae, and acne.<br><br> <strong>Cautions:</strong> Systemic corticosteroid therapy should be avoided in patients with psoriasis , as subsequent reduction commonly followed by a severe and persistent exacerbation; growth and development in infants & children on prolonged therapy should be observed; withdrawal of corticosteroid therapy should be gradually tapered to avoid symptoms of acute adrenal insufficiency.<br><br>
<strong>Dosage & admin:</strong> By mouth: Adults:
1. Rheumatoid arthritis & other rheumatic conditions: Initially 1-2.5mg daily; maintenance 0.5-1.5mg.
2. Acute rheumatic fever: 6-8mg daily; maintenance minimum effective dose.
3. Asthmatic attack: Initially 3.5-4.5mg, maintenance, minimum effective dose; chronic refractory asthma, 3.5mg daily, maintenance 0.5-2.5mg daily.
4. Allergic dermatosis: 2.5-4.5mg daily. 5. Inflammatory ocular conditions: 2.5-4.5mg daily; maintenance, minimum effective dose. Children: Under 1 year, not recommended; 1-7 years, 1/4 to 1/2 adult dose; 7-12 years 1/2 to 3/4 adult dose.
By injection: (Specially in shock, adrenal crisis
& acute conditions).
Adults: 4-20mg i.v repeated 3 or 4 times daily
if required.
Children: upto 1 year 1 mg; 1-5 years, 2mg; 6- 12 years 4mg. All by i.v injection.
  </p>
        </div><!-- collapsible -->
  

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>BETNELAN Tab. GlaxoSmithKline</h3>
            <p>Betamethasone 0.5mg/tablet 500's pack: 360.00 MRP</p>   
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="DEXAMETHASONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> DEXAMETHASONE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> DEXAMETHASONE  </h3>
          <p>  DEXAMETHASONE: Tablet/Injection<br><br>
<strong>Ind:</strong> See under betamethasone. Cerebral oedema <br><br>C/I; S/E; <strong>Cautions:</strong> See under betamethasone (above).<br><br>
<strong>Dosage & admin:</strong>
By mouth: Adult, 1.5-3 mg daily in divided doses, reducing by 0.25 or 0.5mg every 3 or 4 days to maintenance 0.5 -1.5mg. daily. Cerebral oedema, initially 4-8 mg daily then 10-20mg daily.
Children, under 1 year, not recommended; 1-7 yrs 1/4 to 1/2 adult dose; 7-12 years. 1/2 to 3/4 adult dose, or 0.010-0.04mg/ kg. body-wt.
By Injection: Adult - acute condition, such as shock, severe allergic reactions, fuliminating infections, hepatic coma and cerebral oedema, 8-40mg by slow i.v injection or infuction. Intra- articular, 2-4mg.
Children- (above acute conditions) 0.25- 0.5mg/kg body-wt. daily by slow i.v injection or infusion.  </p>
        </div><!-- collapsible -->
  

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ALSONE Tab. Alco Pharma</h3>
            <p>Dexamethasone 0.5mg/tablet 200's pack: 80.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>D-CORT Tab. Globe</h3>
            <p>Dexamethasone 0.5mg/tablet 100's pack: 38.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>D-CORT Inj. Globe</h3>
            <p>Dexamethasone sodium phosphate 5mg/1ml ampoule: injection
        10 amps pack: 130.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DECAFOS Inj. Techno Drugs</h3>
            <p>Dexamethasone sodium phosphate 5mg/1ml ampoule: injection
        10 amps pack: 100.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DECASON Tab. Opsonin</h3>
            <p>Dexamethasone 0.5mg/tablet 200's pack: 100.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DECASON Inj. Opsonin</h3>
            <p>Dexamethasone sodium phosphate 5mg/1ml ampoule: injection 5 amps pack: 75.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXA Inj. Renata</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection.
        10 amps pack: 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAM Tab. Medimet</h3>
            <p>Dexamethasone 0.5mg/tablet. 100's pack: 38.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAM Inj. Medimet</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection.
        10 amps pack: 85.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAMET Tab. Rephco</h3>
            <p>Dexamethasone 0.5mg/tablet. 100's pack: 40.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAMET Inj. Rephco</h3>
            <p>Dexamethasone sodium phos. 5mg/1ml ampoule: injection.10 amps pack: 100.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAMIN Tab. Jayson</h3>
            <p>Dexamethasone 0.5mg/tablet.
        100's pack: 42.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAMIN Inj. Jayson</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection 10 amps pack: 120.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAN Tab. Chemist</h3>
            <p>Dexamethasone 0.5 mg/tablet.
        250's pack. 105.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXAN Inj. Chemist</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection 10 amps pack: 133.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXATAB Tab. Renata</h3>
            <p>Dexamethasone 0.5 mg/tablet.
			250's pack. 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXON Inj. Ibn Sina</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection. 10 amps pack: 120.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXTASON Tab. Ziska</h3>
            <p>Dexamethasone 0.5 mg/tablet.
        100's pack. 38.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXTASON Inj. Ziska</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection. 10 amps pack: 90.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEXASONE Tab. Pharmadesh</h3>
            <p>Dexamethasone 0.5mg/tablet.
        100's pack. 46.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>G-DEXAMETHASONE Inj. Gonoshas.</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection 10 amps pack: 98.60 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MERADEXON Tab. Gaco</h3>
            <p>Dexamethasone 0.5mg/tablet.
        100's pack. 50.35 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MERADEXON INJ. GACO</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection 1 ampoule pack: 9.81 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ORADEXON Tab. Nuvista</h3>
            <p>Dexamethasone 0.5mg/tablet.
        500's pack: 445.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ORADEXON Inj. Nuvista</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection 10 amps pack: 198.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>SONEXA Inj. Aristopharma</h3>
            <p>Dexamethasone 5mg/1ml ampoule: injection 10 amps pack: 130.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>STERON Tab. Acme</h3>
            <p>Dexamethasone 0.5mg/tablet.
        100's pack: 38.00 MRP</p>   
        </div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="HYDROCORTISONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> HYDROCORTISONE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>HYDROCORTISONE   </h3>
          <p>  <strong>Ind:</strong> Medical emergencies amenable to intensive corticosteroid therapy e.g. status asthmaticus; acute adrenal crisis; cardiogenic haemorrhagic anaphylactic or septic shock; shock due to burn; overwhelming infections (with chemotherapy); Ulcerative colitis.<br><br>
C/I; S/E; <strong>Cautions:</strong> See under Betamethasone (above).
Adult: Shock, 100-500mg i.v repeated as necessary every 2-6 hours; Status asthmaticus, 500 mg. i.v. stat, may be repeated 4-6 hours later or followed by an infusion of 500 mg. every 4 hours; Acute adrenal crisis, 250 mg. i.v. then approximately 250mg. every 12 hours interval by i.v. infusion; Ulcerative colitis, 100mg. dissolved in 120 ml saline and administered as rectal drip.
Child: Usual doses are 6-10mg/kg body wt. but
50 mg/kg body-wt. may be required if life threatening states. The dose should not fall below 25mg daily.  </p>
        </div><!-- collapsible -->
  		
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ANACORT Inj. Techno Drugs</h3>
  		    <p>Hydrocortisone sodium succinate 100mg/2ml vial: injection 100mg (2ml) vial: 45.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>COTSON Inj. Opsonin</h3>
  		    <p>Hydrocortisone sodium succinate 100mg/2ml vial: injection 100mg (2ml) vial: 50.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>G-HYDROCORTISONE Inj. Gonoshasthya</h3>
  		    <p>Hydrocortisone sodium succinate 100mg/2ml ampoule: injection 100mg (2ml) amp x 5's pack: 200.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>HISON Inj. ACI</h3>
  		    <p>Hydrocortisone sodium succinate 100mg/2ml vial: injection 100mg (2ml) vial: 50.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>HYDROCORTISONE MEDO Inj.</h3>
  		    <p>Hydrocortisone sodium succinate 100mg/2ml vial: injection. 100mg (2ml) vial: 59.80 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>HYDROCORTISONE-Rotex Inj. Rotex Medica/City Overseas</h3>
  		    <p>Hydrocortisone sodium succinate 100mg/2ml vial: injection.2ml vial: 56.00 TP</p>   
  		</div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="PREDNISOLONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  PREDNISOLONE  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> PREDNISOLONE  </h3>
          <p>  <strong>Ind:</strong> Bronchial asthma, allergic disorders, rheumatoid arthritis, rheumatic fever, allergic and inflammatory skin diseases. Shock, pulm. oedema, cerebral oedema, status asthmaticus (as parenteral prepn.)<br><br>
C/I; S/E; <strong>Cautions:</strong> See under betamethasone (above)<br><br>
<strong>Dosage & admin:</strong> By mouth: Adult, 10-20 mg daily in divided (2-3) doses reducing by 2.5 or 5mg every 3 or 4 days to maintenance 5-15mg daily.
Child, under 1 year, not recommended; 1-7yrs. 1/4 to half adult dose; 7-12years 1/2 to 3/4 adult dose.
By injection: By i.v or i.m injection, upto 100mg (as sodiumphosphate); by i.m. injection, prednisolone acetate 25-100mg. Parenteral route usually used in acute conditions. After remission of acute symptoms, continue for a few days orally as mentioned above.  </p>
        </div><!-- collapsible -->

		<div data-role="collapsible"> <!-- collapsible -->
		        <H3>CORTAN Tab. Incepta </H3>
		        <p>Prednisolone 5mg, 10mg & 20mg/tablet. 5mg x 200's pack: 150.00 MRP 10mg x 100's pack: 120.00 MRP 20mg x 50's pack: 107.50 MRP</p>
		</div><!-- collapsible -->    

		<div data-role="collapsible"> <!-- collapsible -->
		        <H3>DELTACORT Tab. Desh</H3> 
		        <p>Prednisolone 5mg/tablet.
		        5mg x 500's pack: 350.00 MRP</p>
		</div><!-- collapsible -->         

		<div data-role="collapsible"> <!-- collapsible -->
		         <H3>DELTAPRED Tab. </H3>
		         <P>Ziska Prednisolone 5mg/tablet.
		         5mg x 500's pack: 350.00 MRP</p>
		</div><!-- collapsible --> 


		<div data-role="collapsible"> <!-- collapsible -->
		        <H3>DELTASONE Tab. Renata </H3>
		        <p>Prednisolone 5mg/tablet.
		        5mg x 500's pack: 400.00 MRP
		        10mg x 100's pack: 144.00 MRP</p>
		</div><!-- collapsible --> 

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PRECODIL Tab. Opsonin</h3>
  		    <p>Prednisolone 5mg & 20mg/tablet 5mg x 100's pack: 50.00 MRP 20mg x 60's pack: 129.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREDNICORTIL Tab. Gaco</h3>
  		    <p>5mg x 100's pack: 64.93 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREDNISOLONE Tab. Ambee</h3>
  		    <p>5mg x 500's pack: 330.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>PREDNISOLONE Tab. GlaxoSmithKline</h3>
  		    <p>5mg x 500's pack: 400.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>REDNISONE Tab. Rephco</h3>
  		    <p>5mg x 100's pack: 75.00 MRP</p>   
  		</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="METHYL PREDNISOLONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  METHYL PREDNISOLONE  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> METHYL PREDNISOLONE  </h3>
          <p>  Methyl prednisolone acetate 40mg/ml; 1ml & 2ml vial: injection<br><br>
<strong>Ind:</strong> Rheumatoid arthritis, inflammatory and allergic conditions, osteoarthritis, cerebral oedema.<br><br>
C/I; S/E; <strong>Cautions:</strong> See under betamethasone (above).<br><br>
<strong>Pregnancy & lactation:</strong> There are no adequate & well-controlled studies in pregnant women. As animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Prednisolone is excrated in breast milk, it is reasonable to assume that all corticosteroids are. No specific data in known for methyl
prednisolone acetate.<br><br>
<strong>Dosage & admin:</strong> Rheumatoid & osteoarthritis: The dosage depends upon the size of the joint and severity of the conditions; max. dose may be upto 120mg. Injection may be repeated if needed at an interval of 1 to 5 or more weeks depending upon the degree of relief obtained from initial dose.
Dermatological conditions: 40-120mg (1-3m1). Allergic conditions: 80-120mg (2-3m1). Collagen diseases: 40-120mg (1-3m1) repeated
2-3 weekly if required.
Adrenogenital syndrome: 40mg (1m1) every 2 weeks.
Note: For further information, please consult manufacturer's literature.  </p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="METHYL SODIUM" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  METHYL PREDNISOLONE SODIUM  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> METHYL PREDNISOLONE SODIUM
SUCCINATE  </h3>
          <p>   Methyl prednisolone sodium succinate 40mg,125mg, 500mg & 1gm vial: injection <strong>Ind:</strong> See just below with the dosage.<br><br>
C/I; S/E; <strong>Cautions:</strong> See above under the text of betamethasone.<br><br>
<strong>Pregnancy & lactation:</strong> There are no adequate & well-controlled studies in pregnant women. As animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Prednisolone is excrated in breast milk, it is reasonable to assume that all corticosteroids are. No specific data in known for methyl prednisolone sodium succinate.
Indications & Dosage: 1. As adjunctive therapy in life-threatening conditions- the recommended dose is 30mg/kg given i.v over a period of at least 30 minutes; this dose may be repeated evry 4-6 hours for up to 48 hours.
2. Corticosteroid responsive diseases in exacerbation and/or unresponsive to standard therapy- suggestive schedule:
i. Rheumatic disorders: 1gm/day for 1, 2, 3 or 4 days i.v or 1gm/month for 6 months i.v.
ii. Systemic lupus erythematosus (SLE):
1gm/day for 3 days i.v.
iii. Multiple sclerosis: 1gm/day for 3 days or 5 days i.v.
iv. Oedematous states: e.g glomerulonephritis, lupus nephritis: 30mg/kg every other day for 4 days i.v or 1gm/day for 3, 5 or 7 days i.v.
3. Mild to moderately emetogenic chemotherapy: Administer 250mg i.v over at least 5 minutes 1 hour before chemotherapy, at the initiations of chemotherapy , & at the time of discharge. A chlorinated phenothiazine may also be used with the first dose of methyl prednisolone sodium succinate injection for increased effect. 4. Severely emetogenic chemotherapy: Administer methyl prednisolone sodium succinate 250mg i.v over at least 5 minutes with appropriate dosage of metoclopramide or a butyrophenone 1 hour before chemotherapy, then 250mg i.v at the initiation of chemotherapy & at time of discharge.
5. In other indications: Initial dosage will vary from 10 to 500mg depending on the clinical problem being treated. Larger dosage may be required for short-term management of severe, acute conditions. The initial dose, up to 250mg, should be given i.v over a period of at least 5 minutes; subsequent dosage may be given i.v or i.m at intervals dictated by the patients response & clinical conditions.
Corticosteroid therapy is an adjunct to, & not replacement for, conventional therapy.
Dosage may be reduced for infants & children but should be governed more by severity of the condition & response of the patient than by age or size. It should not be less than 0.5mg/kg
every 24 hours.
Methyl prednisolone sodium succinate may be
administered by i.v or i.m injection or by i.v infusion, the preffered method for initial emergency use being intravenous injection. Note: For further information, please consult manufacturer's literature. </p>
        </div><!-- collapsible -->
        
                <div data-role="collapsible"> <!-- collapsible -->
                  <h3> SOLU-MEDROL Inj. Pharmacia-Pfizer/
        Janata </h3>
                  <p> Methyl prednisolone sodium succinate 40mg,
        125mg, 500mg & 1gm vial: injection 40mg vial x l's pack: 299.03 MRP 125mg vial x 1's pack: 498.40 MRP 500mg vial x 1's pack: 1011.05 MRP 1gm vial x 1's pack: 1685.17 MRP  </p>
                </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="TRIAMCINOLONE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> TRIAMCINOLONE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> TRIAMCINOLONE: Tablet/Injection  </h3>
          <p>  <strong>Ind:</strong> Allergic disease, dermatoses or generalized rheumatoid arthritis and other connective tissue disorders. May also be given by intra-articular or intra-bursal administration in traumatic arthritis, synovitis, bursitis and tendinitis.<br><br>
<strong>C/I:</strong> Local for systemic viral infections, tuberculosis, active peptic ulcer, acute glomerulonephritis. Pregnancy is relative contraindication for corticosteroid therapy particularly in the first trimester of pregnancy. Local administration is contraindicated in presence of active infections.<br><br>
<strong>S/E:</strong> Cushingoid syndrome, weakness, bruising or purpura, masking of infections, activation or aggravation of peptic ulcer, activation of latent or aggravation of existing diabetes, altered menstrual cycle, hirsutism, acnel form eruptions. There should be gradual termination in dosage.<br><br>
<strong>Dosage & admin:</strong> For children from 6 to 12 years, initial dose is 40mg. Initial systemic dose for adults and children over 12 years is 40 to 80mg. For adults maximum daily dose is 80 to 100mg. For local areas, dose for adults is upto 10mg for smaller and 40mg for larger areas.  </p>
        </div><!-- collapsible -->
  		
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>CYNOCORT Inj. Techno Drugs</h3>
  		    <p>Triamcinolone acetonide 40mg/ml: i.m injection. 1ml amp: 60.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>KENACOL Tab. Skylab</h3>
  		    <p>Triamcinolone BP 4mg/tablet
  		100's pack: 290.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>KENACORT-A Inj. Squibb/ Kapricorn</h3>
  		    <p>Triamcinolone acetonide 40mg/ml: i.m injection.
  		1ml amp: 68.27 MRP</p>   
  		</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->


<div data-role="page" id="Female sex hormones" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Female Sex hormones   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

		
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ESTRIOL (Oestrogens) </h3>
          <p>  Estriol is a natural oestrogenic hormone.
<strong>Ind:</strong> See below under the individual preparation. <br><br><strong>C/I:</strong> Pregnancy; thrombosis; known or suspected oestrogen-dependent tumours; undiagnosed vaginal bleeding; a history of manifestation or deterioration of otosclerosis during pregnancy or previous use of steroids.<br><br>
<strong>S/E:</strong> Breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high a dosage. Headache, hypertension, leg cramps and vision disturbances are seldom observed. In general most of these adverse reactions disappear after the first treatment week.<br><br>
<strong>Pregnancy & lactation:</strong> This medicine is contraindicated during pregnancy. There are insufficient data on the use of this medicine during breast-feeding to assess potential harm to the inant. It is known, however, that estriol is excreted in breast milk and may decrease milk production.<br><br>
Warnings & pre<strong>Cautions:</strong>
1. In order to prevent endometrial stimulation, the daily dose should not exceed 8mg (or 1 application of intravaginal cream- 0.5mg estriol) nor should this maximum dose be used for longer than several weeks.
2. During prolonged treatment with oestrogens, periodic medical examinations are advisable.
3. With vaginal infections, a concomitant specific treatment is recommended.
4. Patients also should be monitored for the other adverse effects as with other oestrogens.
<br><br><strong>Dosage & admin:</strong> see below under the
individual preparation.  </p>
        </div><!-- collapsible -->

  	<div data-role="collapsible"> <!-- collapsible -->
          <h3>  OVESTIN Tab. Nuvista </h3>
          <p>  Estriol 1mg/tablet.
<strong>Ind:</strong> See under the doses.<br><br>
C/I; S/E; Warnings & Pre<strong>Cautions:</strong> See above under the text of estriol.
Indications & Dosage: Atrophy of the lower urogenital tract related to oestrogen dficiency leading to dyspareunia, dryness and itching, recurrent infections of the va gina and lower urinary tract including mild urinary incontinence: 4-8mg per day for the first week, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1-2mg per day) is reached. In certain cases of urinary incontinence a higher maintenance dosage will be required.
Pre- & postoperative therapy in post-menopausal women undergoing vaginal surgery: 4-8mg per day in the 2 weeks before surgery; 1-2mg per day in the 2 weeks after surgery.
Climacteric complaints such as hot flushes and night sweating: 4-8mg per day during the first week, followed by a gradual reduction. For maintenance therapy the first week, followed by a gradual reduction. For maintenance therapy the lowest effective dosage should be used.
A diagnostic aid in case of a doubtful atrophic cervical smear: 2-4mg per day for 7 days before taking the next smear.
Infertility due to cervical hostility: In general 1-2mg per day on days 6-15 of the menstrual cycle. However, for some patients dosages as low as 0.25mg per day are sufficient. Whereas others may need up to 8mg per day. Therefore, the dosage should be increased each month until an optimal effect on the cervical mucus is obtained.
Administration: Ovestin tablets should be taken orally, preferably with some fluid. It is important that the total daily dose is taken at one time.
30's pack: 240.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> OVESTIN Cream Nuvista  </h3>
          <p> Estriol 1mg/gram: cream.<br><br>
<strong>Ind:</strong> See under the doses.<br><br>
C/I; S/E; Warnings & Pre<strong>Cautions:</strong> See above under the text of estriol. As ovestin cream is applied to the mucosal surfaces, it may cause local irritation or itching.
Indications & Dosage: Atrophy of the lower urogenital tract related to oestrogen dficiency leading to dyspareunia, dryness and itching, recurrent infections of the va gina and lower urinary tract including mild urinary incontinence: 1 application per day for the first week, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1 application twice a week) is reached. In certain cases of urinary incontinence a higher maintenance dosage will be required.
Pre- & postoperative therapy in post- menopausal women undergoing vaginal surgery: 1 application per day in the 2 weeks before surgery; 1 application twice a week in the 2 weeks after surgery.
A diagnostic aid in case of a doubtful atrophic cervical smear: 1 application on alternate days in the week before taking the smear. Administration: Ovestin cream should be administered intravaginally by means of a calibrated applicator before retiring at night. 1 application (applicator filled to the ring mark) contains 0.5gm ovestin cream which corresponds with 0.5mg estriol.
15gm tube with applicator: 557.50 MRP   </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->




    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  CONJUGATED OESTROGENS </h3>
          <p> Conjugated oestrogens (equine) 0.625mg & 1.25mg/tablet.<br><br>
<strong>Ind:</strong> Menopausal & post-menopausal oestrogen replacement; post-menopausal osteoporosis; senile vaginitis, functional amenorrhoea, prostatic carcinoma.<br><br>
<strong>C/I:</strong> Pregnancy. Uterine myomatosis. Endometriosis. Uterine or mammary carcinoma. Severe cardiac, hepatic or renal disease. History of thromboembolic disease. Undiagnosed vaginal bleeding.<br><br>
<strong>S/E:</strong> Nausea & vomiting, wt. gain, breast enlargement and tenderness, withdrawal bleeding, sodium retention with oedema, changes in liver function, jaundice, rashes and chloasma, depression, headache, endometrial carcinoma in post-menopausal women.
<br><br><strong>Dosage & admin:</strong> Adult: Menopausal, usually 0.625mg or 1.25mg daily for 21 days starting on 5th day of menstruation then repeat after 7 days. Postmenopausal osteoporosis, cyclically 0.625mg or 1.25mg daily. Functional amenorrhoea, 0.625mg or 1.25mg daily for 21 days. For the last 7 days progesteron therapy should be added.
Child: Not applicable.   </p>
        </div><!-- collapsible -->
      
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>EQUIN 0.6 Tab. Aldo-Union, Spain/Medinma</h3>
            <p>Conjugated oestrogens (equine) 0.625mg/tablet. 0.625 mg x 28's: 246.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PREMARIN Tab. Ayerst</h3>
            <p>1.25 mg x 100's: 349.70 MRP
        Note: Prices could not be revised; preparations may not be available.</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PREMARIN I.V. Inj. Ayerst</h3>
            <p>Adult: By slow i.v injection 25mg. repeat after 6-12 hours if required. Child: Not applicable. 1 amp. 173.50 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PREMARIN Vaginal Cream Ayerst.</h3>
            <p>Adult: 1-2gm daily topically or intravaginally using calibrated applicator for 3 weeks followed by 1 week rest.
        Child: Not applicable.
        42.5 gm. tube: 170.80 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PREMICON Tab. Techno Drugs</h3>
            <p>Conjugated oestrogens USP 0.625mg/tablet (f.c). 0.625mg x 28's: 140.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


      <div data-role="collapsible-set" data-theme="b">
       
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> PROGESTERONE: Tablet/Gel/Pessary  </h3>
          <p>  Description & <strong>Mode of action:</strong> Progesterone is a female sex hormone produced by the corpus luteum, which develops from the ruptured ovarian follicle immediately after ovulation i.e the empty follicle that remains when the ovum emerges at mid-cycle. Progesterone then promotes transformation of the oestrogen-primed endometrium, as a result, the endometrium is
transformed into an environment that is receptive to embryo implantation and able to support early pregnancy. Synchronization between embryo development and endometrial receptivity begins with ovulation and production of progesterone by the corpus luteum. The embryo arrives in the uterine cavity from the fallopian tube 4 to 5 days after ovulation-cycle day 18 or 19 at the morula stage, but does not implant until day 20 or 21 at the blastocyst stage. At that time, there is peak activity of the glands of the endometrium and it is best prepared to support the embryo. Thus, it is clear that the establishment of pregnancy depends not only on successful fertilisation and embryo quality but on endometrial receptivity to embryo implantation.
Progenterone is clearly a critical hormone in achieving and maintaining pregnancy. This hormone is essential for the preparation of the endometrium for implantation; it is also essential for the maintenance of a viable pregnancy. If progesterone is withdrawn, miscarriage will occur. <br><br><strong>Ind:</strong> See below under individual preparation.
<br><br><strong>C/I:</strong> Progesterone should not be used in individuals with any of the following conditions:<br>
1. Pregnancy or suspected pregnancy.<br>
2. Known sensitivity to progesterone.<br>
3. Undiagnosed vaginal bleeding.<br>
4. Liver dysfunction or disease.<br>
5. Known or suspected malignancy of the breast
or genital organs.<br>
6. Missed abortion.<br>
7. Active thrombophlebitis or thromboembolic
disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders.
Adverse effects: Nausea, weight-gain, headache, depression, changes in libido, breast enlargement, altered menstrual cycles, virilisation of foetus, acne, urticaria.
Also see under the individual preparation. Warnings: The physician be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). If any of these occur or be suspected, the drug should be discontinued immediately. Progesterone and progestins have been used to prevent miscarriage in women with history of recurrent spontaneous pregnancy losses. But, no adequate evidence is available to show that they are effective for this purpose.<br><br>
Pre<strong>Cautions:</strong>
1. The pretreatment physical examination should include special reference to breast and pelvic organs, as well as papanicolaou smear.
2. In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional causes should be considered; in cases of undiagnosed vaginal bleeding, adequate diagnostic measures should be undertaken.
3. Because progestogens may cause some degree of fluid retention, conditions which might be influenced by this factor (e.g epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.
4. The pathologist should be advised of
progesterone therapy when relevant specimens are submitted.
5. Patients who have a history of psychic depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
6. A decrease in glucose tolerance has been observed in a small percentage of patients on estrogen-progestin combination drugs. The mechanism of this decreaes is not known. For this reason, diabetic patients should be carefully observed while receiving progestin therapy.
7. In case of intravaginal gel preparation or
pessary, the patient should be advised not to use concurrently with other local intravaginal therapy. If it is needed to be used concurrently, there should be at least a 6-hour interval.
<br><br><strong>Dosage & admin:</strong> Please see below under the individual preparation.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  CRINONE 8% Gel Serono/Janata Healthcare </h3>
          <p>   Crinone is a bioadhesive vaginal gel preparation, containing micronized progesterone 8% in an emulsion system, which is contained in single use, one piece polyethylene vaginal applicators.
(There is also another preparation with low strength - Crinone 4%, not available in our market).<br><br>
<strong>Ind:</strong> i. Assisted reproductive technology - Crinone 8% (90mg) is indicated for progesterone supplementation or replacement as part of an assisted reproductive technology ('ART') treatment for infertile women with progesterone deficiency.
ii. Secondary amenorrhea - Crinone 4% is indicated for the treatment of secondary amenorrhea. Crinone 8% (90mg) is indicated for use in women who have failed to respond to treatment with crinone 4%.<br><br>
<strong>C/I:</strong> Please see above under the text of
progesterone.
Adverse reactions: Assisted reproductive technology (ART): In a study of 61 women with ovarian faliure undergoing a donor oocyte t ransfer procedure receiving progesterone 8% (90mg) twice daily, treatment-emergent adverse events occurring in 5% or more of the women are as follows:
Body as a whole- bloating, cramps, pain;
Central and peripheral nervous system- dizziness, headache; Gastrointestinal system- nausea; Reproductive- breast pain, genital moniliasis, vaginal discharge; Skin and appendages- genital pruritus.
In a second study of 139 women using progesterone 8% (90mg) once daily for luteal
phase support while undergoing an 'in vitro fertilization' procedure, treatment-emergent adverse events reported in 5% or more of the women are as follows:
Body as a whole- abdominal pain, perineal pain; Central and peripheral nervous system- headache; Gastrointestinal system- constipation, diarrhea, nausea, vomiting; Musculoskeletal system- arthralgia; Psychiatric- depression, libido decreased, nervousness, somnolence; Reproductive- breast enlargement, dyspareunia; Urinary system- nocturia.
Secondary amenorrhea:
In three studies, 127 women with secondary amenorrhea received estrogen replacement therapy and progesterone 4% or 8% every other
day for six doses. Treatment emergent adverse events during estrogen and progesterone treatment that occurred in 5% or more of women are as follows:
Body as a whole- abdominal pain, appetite increased, abnormal crying, allergic reaction, allergy, asthenia, edema, face edema, fever, hot flushes, influenza-like symptoms, water retention, xerophthalmia decreased, asthenia, edema, face edema, fever, hot flushes, influenza-like decreased, asthenia, edema, face edema, fever, hot fiushes, influenaz-like symptoms, water refention, xerophthalmia. bloating, cramps, fatigue; Central and peripheral nervous system- headache; Gastrointestinal system- nausea; Musculoskeletal system- back pain, myalgia; Psychiatric- depression, emotional lability, sleep disorder; Reproductive- vaginal discharge; Resistance mechanism- upper respiratory tract infection; Skin and appendages- genital pruritus.
Additional adverse events reported in women at a frequency < 5% in progesterone ART and secondary amenorrhea studies include:
Body as a whole- abnormal crying, allergic reaction, allergy, appetite decreased, asthenia, edema, face edema, fever, hot flushes, influenza- like symptoms, water retention, xerophthalmia; CVS- syncope; Central & peripheral nervous system- migraine, tremor; Autonomic nervous system- dry mouth, increased sweating; Gastrointestinal- dyspepsia, eructation, flatulence, gastritis, toothache; Metabolic & nutritional- thirst; Musculoskeletal system- leg cramps, leg pain, skeletal pain; Neoplasm- benign cyst; Platelet, bleeding & clotting- purpura; Psychiatric- aggressive reactions, forgetfulness, insomnia; RBC- anemia;
Reproductive- dysmenorrhea, premenstrual tension, vaginal dryness; Resistance mechanism- infection, pharyngitis, sinusitis, urinary tract infection; Respiratory system- asthma, dyspnea, hyperventilation, rhinitis;
Skin & appendages- acne, pruritis, rash, seborrhea, skin discoloration, skin disorder, urticaria; Urinary system- cystitis, dysuria, micturition frequency; Vision disorder- conjunctivitis.<br><br>
Warnings & <strong>Cautions:</strong> Please see above under
the text of progesterone.<br><br>
<strong>Pregnancy & lactation:</strong> Progesterone 8% (90mg) has been used to support embryo implantation and maintain pregnancies through its use as part of ART treatment regimens in two clinical studies. In the first study, 54 women were treated with progesterone 8%. Out of them clinical
pregnancies occurred in 26 women (48%). Among these 26 pregnancies, one woman had an elective termination of pregnancy at 19 weeks due to congenital malformations (omphalocele) associated with a chromosomal abnormality; one woman pregnant with triplets had an elective termination of her pregnancy; seven women had spontaneous abortions; and 17 women delivered 25 apparently normal newborns.
In the second study, progesterone 8% (90mg) was used in the luteal phase support of women undergoing 'in vitro fertilization (IVF)' procedures. In this multi-centre, open-label study, 139 women received progesterone 8% (90mg) once daily beginning within 24 hours of embryo
transfer and continuing through day 30 past- transfer. Clinical pregnancies assessed at day 90 post-transfer were seen in 36 women (26%). 32 women (23%) delivered newborns & 4 women (3%) had spontaneous abortions. Of the 47(?) newborns delivered, one had a teratoma associated with a cleft plate; one had respiratory distress syndrome; 44 were apparently normal & one has lost to followup.
Detectable amounts of progestins have been identified in the milk of mothers receiving them. The effect of this on the nursing infant has not been determined.<br><br>
<strong>Dosage & admin:</strong> Assisted reproductive technology (ART): Progesterone 8% (90mg) is administered vaginally at dose of 90mg once daily in women who require progesterone supplementation. Progesterone 8% (90mg) is administered vaginally at a dose of 90mg twice daily in women with partial or complete ovarian failure who require progesterone replacement. If pregnancy occurs, treatment may be continued until placental autonomy is achieved, up to 10-12 weeks.
Secondary amenorrhea: Progesterone 4% is administered vaginally every other day up to a total of six doses. For women who fail to respond, a trial of progesterone 8% (90mg) every other day up to a total of six doses may be instituted.
It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered dose not increasee the amount of progesterone absorbed.
How to use crinone: Please consult the manufacturer's insert.<br><br>
<strong>Drug Inter:</strong> No drug interactions have been assessed with crinone.
Price:
Crinone 8% single-use prefilled applicator x 15's pack: 4288.53 MRP </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  CYCLOGEST Pessary Alpharma/Tajarat </h3>
          <p>  Each pessary contains 400mg progesterone: For vaginal or rectal insertion.<br><br>
<strong>Ind:</strong> Habitual abortion, threatened abortion, pre- menstrual syndromde, post- natal depression, & luteal phase support.<br><br>
<strong>C/I:</strong> See above under the text of progesterone. <br><br><strong>S/E:</strong> See above under the text of progesterone. Menstruation may occur earlier than expected, or be delayed. Soreness, diarrhoea and flatulence with rectal application. Leakage of pessary base. Precautions & warnings: See above under the text of progesterone.
Hepatic dysftunction, conditions that may be hromone sensitive. Warnings: Use rectally if barrier methods of contraception are used, if patient has vaginal infection, recurrent cystitis, or has recently given birth. Use vaginally where colitis or faecal incontinence present.
Dosage & application: Habitual abortion: 400mg twice a day rectally or vaginally for 3 months. Threatened abortion: Starting dose 800mg rectally, followed by 400mg every 12 hours, till bleeding stops. Pre-menstrual syndrome: Start on day 14 of cycle with 200mg or 400mg once or twice a day, vaginally or rectally, continue until menstruation starts; if symptoms present at ovulation, start by day 12.  </p>
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->




        <div data-role="collapsible-set" data-theme="e">
          <div data-role="collapsible"> <!-- collapsible -->
            <h3> NORETHISTERONE: Tablet  </h3>
            <p>   Norethisterone is a synthetic progesterone hormone. It is available 5mg tablet.<br><br>
<strong>Ind:</strong> Postponement of menstruation; dysmenrrhoea, menorrhagia and premenstrual syndrome; metropathia haemorrhagica; Polymenorrhoea; endometriosis.<br><br>
C/I; S/E; Warnings; <strong>Cautions:</strong> Please see above under the text of progesterone.<br><br>
<strong>Dosage & admin:</strong> Adult: Postponement of mens.- 5mg 3 times daily starting 3 days before expected onset of menstruation. Dysmenorrhoea- 5mg 3 times daily for 20 days starting on 5th day of menstruation, then 8 tablet-free days. Maintain treatment for 3 or 4 cycles. Menorrhagia and pre-menstrual syndrome. 5mg. 2 or 3 times daily from day 1926 of cycle.
Child: Not applicable. </p>
          </div><!-- collapsible -->
         
          <div data-role="collapsible"> <!-- collapsible -->
            <h3> ORGAMETRIL Tab. Nuvista  </h3>
            <p>  Lynestrenol 5mg/tablet.
It is a progestogenic agent specially effective in correcting different menstrual disorders due to hormonal imbalance.
Indications & Dosage:
Polymenorrhoea: 1 tablet daily on days 14-25 of the cycle.
Menorrhagia & Metrorrhagia: 2 tablets daily for 10 days. Usually the bleeding will cease within a few days after the start of the treatment. Treatment is repeated during
the next 3 menstrual cycles with 1 tablet daily on days 14-25 of each cycle.
Further diagnostic procedures are necessary if the complaints do not disappear during or after this treatment.
Selected cases of primary and secondary amenorrhoea and oligomenorrhoea: Treatment should start with the administration of an estrogen, e.g 0.02-0.05mg ethinylestradiol per day for 25 days. In conjunction with this, 1 tablet daily of Orgametril is administered on days 14-25.
After cessation of treatment, a withdrawal bleeding usually occurs within 3 days. Treatment is resumed (second cycle) starting on day 5 of this withdrawal bleeding with the estrogen given on days 5-25 of the cycle and again with 1 tablet daily of Orgametril on days 14-25.
This treatment should be repeated for at least another cycle.
Premenstrual syndrome: 1 tablet daily on days 14-25 of the cycle.
Endometriosis: 1-2 tablets daily for at least 6 months.
Selected cases of endometrial carcinoma: 6-10 tabs. daily for prolonged periods.
Benign breast disease: 1 tablet daily on days 1425 of the cycle or at least 3-4 months. Suppression of menstruation, ovulation and ovulation pain; dysmenorrhoea: Treatment with 1 tablet daily should start preferably on day 1, but no later than day 5 of the cycle. The treatment can be continued for many months (without tablet-free days). If in spite of treatment, a breakthrough bleeding occurs, the dosage should be increased to 2 or 3 tabs. daily for 3-5 days.
Postponement of menstruation: Treatment with 1 tablet daily should start preferably 2 weeks before the expected onset of menstruaton. If treatment is started less than 1 week before the expected onset of menstruation the dosage should be 2-3 tabs. per day. However, in that case a delay of more than 1 week is undesirable.
The risk of breakthrough bleeding increases if treatment is started later. Therefore, treatment should not be started later than 3 days before the expected onset of menstruation.
As an adjunct to estrogen therapy in peri- and postmenopause, in order to avoid
endometrial hyperplasia: 1/2 - 1 tablet daily for 12-15 days per month, e.g. for the first 2 weeks of every calendar month; the estrogen may be administered daily without tablet free
intervals at the lowest effective dose. Administration: Orgametril tablet should
be taken orally with some fluid.
Note: Throughout the text, take the first day of the menstrual bleeding as day 1 of the cycle.
<br><br><strong>C/I:</strong> Please see above under the text of progesterone.
A/R: During continuous treatment regimens breakthrough bleeding or spotting will occur frequently (over 10%) during the first two months.
During cyclic treatment regimens breakthrough bleeding and spotting will be seen occasionally (1-10%).
Temporarily increasing the dose will control the bleeding in most cases.
Other adverse effects- almost same as other progestogenic hormones.
Cautions & warnings: Please see above under the text of progesterone.
30's pack: 268.80 MRP  </p>
          </div><!-- collapsible -->
        

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>NORCOLUT Tab. Gedeon Richter/City Overseas</h3>
              <p>Norethisterone 5mg/tablet.
          20's pack: 115.00 TP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>NORMENS Tab. Renata</h3>
              <p>Norethisterone 5mg/tablet.
          30's pack: 150.00 MRP</p>   
          </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> PERLUTEX Tab. Leo Pharma/ Kapricorn  </h3>
          <p>  Medroxyprogesterone acetate 5mg/tablet.
<strong>Ind:</strong> Menstrual irregularities and other disorders caused by inadequate endocrine secretion of the corpus luteum hormone, such as- i. functional uterine bleeding, ii. amenorrhoea and oligomenorrhoea, iii. infertility due to inadequate luteal phase, iv. endometriosis.<br><br>C/I; S/E; Warnings & <strong>Cautions:</strong> Please see above under the text of progesterone.
Dosage: Functional uterine bleeding: 5- 10mg daily for 5-10 days commencing on the assumed or calculated 16-21st day of the cycle ï¿¼
so as to complete treatment on the 26th day of the cycle. Treatment should be given for two consecutive cycles. When bleeding occurs from a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetae, in doses of 5- 10mg for 10 days.
Amenorhoea and Oligomenorrhoea: 5-10mg for 10 days starting from the assumed 16th day of the cycle. When indicated, oestrogen therapy should be given prior to Perlutex. Infertility due to inadequate luteal phase: 2.5- 10mg daily from day 16 to day 25. Endometriosis: 5-20mg daily for 3-6 months. Child: Not applicable
20's pack: 212.40 MRP  </p>
        </div><!-- collapsible -->

       </div><!-- collapsible-set -->



  </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->


<div data-role="page" id="Male sex hormones" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Male sex hormones   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 



      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> TESTOSTERONE & ESTERS (Androgen) </h3>
          <p>  Testosterone is the male hormone, indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
It is available in capsule, gel and injection
form for oral, transdermal and parenteral administration.<br><br>
<strong>Ind:</strong> Testosterone is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: 1. Primary hypogonadism (congenital of acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range.
2. Hypogonadotropic hypogonadism (congenital or acquired): Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range.
(Symptoms of hypogonadism include: Inpotence, decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics, osteoporosis).
3. Inoperable mammary carcinoma.<br><br>
<strong>C/I:</strong> Testosterone is contraindicated in prostatic
or mammary carcinoma in the male; nephrosis; hypercalcaemia; pregnancy & breast-feeding. Testosterone is not indicated for use in women and must not be used in women (except in inoperable mammary carcinoma)<br><br>
<strong>S/E:</strong> Sodium retention with oedema; increase in weight; hypercalcaemia, increased bone growth, priapism, precocious sexual development,
gynecomastia and premature closure of epiphyses in pre-pubertal males; virilism in women, and suppression of spermatogenesis in men.
Other side-effects include-allergic reaction, acne, alopecia, asthenia, depression, headache, hypertension, nausea or vomiting, changes in skin color, swelling of the ankles, breathing disturbances, abdominal pain or discomfort and fatigue.<br><br>
<strong>Cautions:</strong> Cardiac, renal or hepatic impairment, epilepsy, migraine, hypertension,
ischaemic heart disease; skeletal metastases; pre- pubital boys; elderly.<br><br>
<strong>Pregnancy & lactation:</strong> Testosterone is not indicated for use in women and must not be used in women. In women it is only indicated in inoperable mammary carcinoma, but in that case it should be avoided during pregnancy and lactation.
Dosage: See below under individual preparations.  </p>
        </div><!-- collapsible -->

      <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ANDRIOL TESTOCAPS Cap. Nuvista </h3>
          <p>  Testosterone undecanoate 40mg/capsule (testocaps).
Dose: Initially 120-160mg daily for 2-3 weeks is adequate, followed by a maintenance dosage of 40-120mg daily.
30's pack: 492.30 MRP  </p>
        </div><!-- collapsible -->

       <div data-role="collapsible"> <!-- collapsible -->
          <h3> SUSTANON 250 Inj. Nuvista  </h3>
          <p>   Testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg, testosterone decanoate 100mg/ml; 1m1 ampoule: injection.
Dose: Adult: By deep i.m injection 1ml every 3 weeks. (In mammary carcinoma dose or frequency may be increased).
Child: Not applicable
1ml ampoule: 129.53 MRP </p>
        </div><!-- collapsible --> 

	 <div data-role="collapsible"> <!-- collapsible -->
          <h3> SUSTOGEN Inj. Techno Drugs  </h3>
          <p>  Testosterone BP 250mg/ml; 1ml ampoule: injection.
Dose: Adult: By deep i.m injection 1ml every 3 weeks. (In mammary carcinoma dose or frequency may be increased).
Child: Not applicable
1m1 ampoule: 95.00 MRP  </p>
        </div><!-- collapsible -->

      <div data-role="collapsible"> <!-- collapsible -->
          <h3>  Y-45 Gel Incepta </h3>
          <p>  Testosterone USP 1% (10mg/gm): gel preparation <br><br><strong>Ind:</strong> See above under the text.<br><br>
<strong>S/E:</strong> See above under the text. Other side-effects include: an allergic reaction, acne, alopecia, asthenia, depression, gynecomastia, headache, hypertension, nausea or vomiting, changes in skin color, swelling of the ankles, breathing disturbances, too frequent or prolonged erections; abdominal pain or discomfort, fatigue.<br><br>
<strong>Dosage & admin:</strong> Adult: The recommended starting dose of Y-45 gel is 5gm applied once daily (preferably in the morning) to clean, dry, intact skin of the shoulders, upper arms and/or abdomen. Serum testosterone levels should be measured approximately 14 days after initiation of therapy to ensure proper dosing. If the serum testosterone concentration is below the normal range, or if the desired clinical response is not achieved, the daily Y-45 gel dose may be increased from 5gm to 7.5gm and from 7.5gm to 10gm as instructed by the physician. Y-45 gel must not be applied to the genitals.
Children & adolescents: Y-45 gel has not been clinically evaluated in males under 18 years of age.
20gm gel tube: 200.00 MRP  </p>
        </div><!-- collapsible -->
        
      </div><!-- collapsible-set -->
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->


<div data-role="page" id="Anabolic steroids" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Anabolic steroids   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 



      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  NANDROLONE DECANOATE: Injection </h3>
          <p>   <strong>Ind:</strong> Osteoporosis, debility, convalescence, during
corticosteroid therapy, aplastic anaemia and anaemia of chronic renal failure or malignant disease.<br><br>
<strong>C/I:</strong> Severe hepatic impairment, prostate cancer, male hreast cancer, pregnancy and breast-feeding, porphyria.<br><br>
<strong>S/E:</strong> Acne, sodium retention with oedema, virilisation with high doses including voice changes (sometimes irreversible), amenorrhoea, inhibition of spermatogenesis, premature epiphyseal closure; abnormal liver-function tests reported with high doses; jaundice on prolonged treatment; liver tumours reported occasionally on prolonged treatment with anabolic steroids. <br><br><strong>Cautions:</strong> Cardiac and renal impairment, hepatic impairment , hypertension, diabetes mellius, epilepsy, migraine; monitor skeletal maturation in young patients; skeletal metastases (risk of hypercalcaemia).<br><br>
<strong>Dosage & admin:</strong> Adult: 25-50mg i.m. every three weeks.
Anaemia of chronic renal failure, 100-200 mg weekly by deep i.m. injection; aplastic anaemia, 50-150mg weekly; anaemia due to cytotoxic therapy, 200mg weekly starting 2 weeks prior to cytotoxic therapy and continuing until blood count is normal. Child: Not recommended. </p>
        </div><!-- collapsible -->
  		

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DECABOLON Inj. Techno Drugs</h3>
  		    <p>Nandrolone decanoate 50mg/1ml ampoule: injection
  		1ml ampoule: 112.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>DECA-DURABOLIN Inj. Nuvista</h3>
  		    <p>Nandrolone decanoate 50mg/1ml ampoule: injection
  		1m1 ampoule: 169.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>HYDECA Inj. Chemist</h3>
  		    <p>Nandrolone decanoate 50mg/1ml ampoule: injection
  		1m1 ampoule: 110.00 MRP</p>   
  		</div><!-- collapsible -->
      </div><!-- collapsible-set -->




    <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NANDROLONE PHENYLPROPIONATE: Injection  </h3>
          <p>  <strong>Ind:</strong> Osteoporosis, debility, convalescence, during corticosteroid therapy, refractory anaemias, uraemia.
C/I; S/E; Caution: See above under 'Nandrolone decanoate'.
Adult: 25-50mg i.m weekly.
Child: Not recommended.  </p>
        </div><!-- collapsible -->
      
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ANABOLIN Inj. Techno Drugs</h3>
            <p>Nandrolone phenylpropionate 25mg/1ml ampoule: injection
        5 amps pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DURABOLIN Inj. Nuvista</h3>
            <p>Nandrolone phenylpropionate 25mg/1ml ampoule: injection 5 amps pack: 295.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>HYBOLIN Inj. Chemist</h3>
            <p>Nandrolone phenylpropionate 25mg/1ml ampoule: injection 5 amps pack: 190.00 MRP</p>   
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->


    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="Drugs for Sterility" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs for Sterility   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 



      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CLOMIPHENE  </h3>
          <p> <strong>Ind:</strong> Sterility due to ovulatory failure due to
impaired hypothalamic-pituitary function; oligospermia; secondary amenorrhoea.<br><br>
<strong>C/I:</strong> Liver dysfunction; large ovarian cyst; Endometrial carcinoma, undiagnosed uterine bleeding.<br><br>
<strong>S/E:</strong> Visual disturbances (withdraw), ovarian hyperstimulation (withdraw), hot flushes, abdominal discomfort, occasion-ally nausea, vomiting, depression, insomnia, breast tenderness, weight gain, rashes, dizziness, hair loss.<br><br> <strong>Cautions:</strong> Exclude pregnancy, before and during treatment. Withdraw if visual disturbances occur. <br><br><strong>Dosage & admin:</strong> Adult: 50mg (1 tab) daily for 5 consecutive days starting on within about 5 days of onset of menstrual cycle (preparably 2nd day). Or at any time if cycle has ceased. Ovulation usually occurs 6 to 10 days following the last day of treatment. In absence of
satisfactory result, daily 100mg may be given in the subsequent cycle as a rule for 3 (not more than 6) cycle.
Oligospermia- 50mg daily for 6 weeks.
Secondary amenorrhoea- 50mg daily for 5 days starting at any time.
Child: Not applicable.   </p>
        </div><!-- collapsible -->
  		

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>CLOSTILBEGYT Tab. Egis/City Overseas</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 10's pack: 151.14 TP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>COMIPEN Tab. Pacific</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 30's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>FERMID Tab. Gaco</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 10's pack: 49.95 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>FERTIL Tab. Beximco</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 50's pack: 250.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>OVUCLON Tab. Incepta</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 30's pack: 150.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>OVULET Tab. Renata</h3>
  		    <p>50mg x 10's pack: 100.00 MRP 100mg x 5's pack: 90.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>REOMEN Tab. SK+F</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 20's pack: 200.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>SERPAFAR Tab. Faran Lab. S.a/Maisha Health</h3>
  		    <p>Clomiphene citrate 50mg/tablet. 50mg x 20's pack: 300.00 TP</p>   
  		</div><!-- collapsible -->
      </div><!-- collapsible-set -->



<a href="#" data-role="button"  data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>GONAL-F Inj. Serono/Janata Healthcare<br>
           FOLLITROPIN ALFA  </h3>
          <p>  <strong>Ind:</strong> Sterility due to ovulatory failure due to
impaired hypothalamic-pituitary function; oligospermia; secondary amenorrhoea.<br><br>
<strong>C/I:</strong> Liver dysfunction; large ovarian cyst; Endometrial carcinoma, undiagnosed uterine bleeding.<br><br>
<strong>S/E:</strong> Visual disturbances (withdraw), ovarian hyperstimulation (withdraw), hot flushes, abdominal discomfort, occasion-ally nausea, vomiting, depression, insomnia, breast tenderness, weight gain, rashes, dizziness, hair loss.<br><br> <strong>Cautions:</strong> Exclude pregnancy, before and during treatment. Withdraw if visual disturbances occur. <br><br><strong>Dosage & admin:</strong> Adult: 50mg (1 tab) daily for 5 consecutive days starting on within about 5 days of onset of menstrual cycle (preparably 2nd day). Or at any time if cycle has ceased. Ovulation usually occurs 6 to 10 days following the last day of treatment. In absence of
satisfactory result, daily 100mg may be given in the subsequent cycle as a rule for 3 (not more than 6) cycle.
Oligospermia- 50mg daily for 6 weeks.
Secondary amenorrhoea- 50mg daily for 5 days starting at any time.
Child: Not applicable.  </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->



<a href="#" data-role="button"  data-theme="a">  </a>
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> PUREGON Inj. Nuvista <br>(FOLLITROPIN BETA)  </h3>
          <p> Follitropin beta, the active ingredient is recombinant follicle-stimulating hormone (FSH) as freeze-dried powder in ampoule with solvent & in vial. Ampoule of 50 i.0 and 100 i.0 & vial of 100 i.u: injection.<br><br>
<strong>Ind:</strong> Follitropin is indicated for the treatment of female infertility in the following clinical situations- anovulation (including polycystic ovarian disease, PCOD), in women who have been unresponsive to treatment with clomiphene citrate; controlled ovarian hyperstimulation to induce the developm-ent of multiple follicles in medically assisted reproduction programs (e.g in vitro fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI).<br><br>
<strong>C/I:</strong> Tumours of ovary, breast, uterus, pituitary or hypothalamus; pregnancy or lactation; undignosed vaginal bleeding; hypersensitivity to follitropin; primary ovarian failure; ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease (PCOD); malformations of the sexual organs incompatible with pregnancy; fibroid tumours of the uterus incompatible with pregnancy.<br><br>
<strong>S/E:</strong> Unwanted ovarian hyperstimulation has been observed in a few (about 5%) subjects. Characteristic symptoms of this condition- see under precautions & warnings. There may be some local reactions at the site of injection, such as bruising, pain, redness, swelling and itching, the majority of which are mild.<br><br>
Pre<strong>Cautions:</strong> The presence of uncontrolled nongonadal endocrinopathies (e.g thyroid, adrenal or pituitary disorders) should be excluded. The first injection of follitropin should only be given under direct medical supervision.
Unwanted ovarian hyperstimulation- in the treatment of female patients ultrasonographic assessment of follicular development, and determination of estradiol levels should be performed prior to treatment & at regular intervals
during treatment.
A slightly increased risk of ectopic pregnancy and multiple gestations has been seen. In rare instances, arterio-thromboembolisms may occur with follitropin/hCG therapy.
Warnings: Early ultrasound confirmation should be made whether the pregnancy is intrauterine or ectopic or multiple gestation. Since follicles of over 14mm may lead to pregnancies, multiple pre- ovulatory follicles exceeding 14mm carry the risk of multiple gestations. In that case hCG should be withheld and pregnacy should be avoided in order to prevent multiple gestations.
Rates of pregnancy loss in women undergoing replacement therapy are higher than in the normal population.
Dosage: Anovulation- a sequential treatment is recommended, initially a daily dose of 75 i.0 FSH activity, wihich is to be countinued for at least 7 days; if no ovarian response the daiy sose is then gradually increased until follicle growth ano/or plasma estadiol levels indicate an adequate phrmacodynmaic response. The daily dose is then maintained until prevodulary conditionsare fached when there is ultrasonographic evidence of a dominant follicle of at least 18 mm in diameter and or when plasma estadiol 14 days oftreatmet is suffient to reach this state. The administration of follitro-pin is then discontinued and
ovulation canbe induced by adminusteing human chorionic gonadotropin (hCG).
50 i.0 ampoule with solvent: 1568.00 MRP 100 i.0 ampoule with solvent: 2967.87 MRP 100 i.0 vial (0.5ml): 2967.87 MRP
   </p>
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->



<a href="#" data-role="button"  data-theme="a">  </a>
        <div data-role="collapsible-set" data-theme="b">
          <div data-role="collapsible"> <!-- collapsible -->
            <h3>HUMAN CHORIONIC GONADOTROPHIN (HCG) </h3>
            <p> It is a preparation of a glycoprotein fraction secreted by the placenta & obtained from the urine of pregnant women having the actions of the pituitary luteinizing hormone.<br><br>
<strong>Mode of action:</strong> The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum. In women, chorionic gonadotrophin acts as a surrogate LH- surge that triggers ovulation. Chorionic gonadotrophin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/CG receptor, then acts to trigger ovulation.<br><br>
<strong>Ind:</strong> Chorionic gonadotrophin is indicated in the treatment of :
1. Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Chorionic gonadotrophin is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
2. Anovulatory or oligo-ovulatory women: For induction of ovulation & pregnancy- chorionic gonadotrophin is administered to trigger ovulation and luteinisation in anovulatory or oligo- ovulatory patients after stimulation of follicular growth. 3. In male: Hypogonadotrophic hypogonadism, delayed puberty associated with insufficient gonadotrophic pituitary function & cryptorchidism (not due to anatomical obstruction).<br><br>
<strong>C/I:</strong> Chorionic gonadotrophin is contraindicated for safety reasons in case of:
- Tumours of the hypothalamus and pituitary
gland
- Hypersensitivity to the active substance or to
any of the excipients
- Ovarian enlargement or cyst due to reasons
other than polycystic ovarian disease
- Gynaecological haemorrhages of unknown
aetiology
- Ovarian, uterine, or mammary carcinoma - Extrauterine pregnancy in the previous 3 months
- Active thrombo-embolic disorders.
Chorionic gonadotrophin must not be used when an effective response cannot be obtained, for example:
- Primary ovarian failure
- Malformations of sexual organs incompatible
with pregnancy
- Fibroid tumours of the uterus incompatible
with pregnancy
- Postmenopausal women.<br><br>
<strong>S/E:</strong> Oedema (particularly in males- reduce dose), headache, tiredness, mood changes, gynaecomastia, local reactions; sexual precocity with high doses; may aggravate ovarian hyperstimulation.<br><br>
<strong>Cautions:</strong> Cardiac or renal impairment, asthma, epilepsy, migraine. Treatment requires careful monitoring to avoid the ovarian hyperstimulation syndrome & multiple pregnancy.<br><br>
<strong>Dosage & admin:</strong> In the male: Hypogonadotrophic hypogonadism: 1000-2000 i.0 2 to 3 times per week for at least 3 months before any improvement in spermatogenesis can be expected. If the case is sterility, additional doses of an FSH (containing 75 i.0 FSH) are to be given daily or 2 to 3 times a week. During this treatment testosterone replacement therapy should be suspended. Delayed puberty: 15000 i.0 2 to 3 times a week for at least 6 months.
Cryptorchidism: Under 2 years of age 250 i.0 twice weekly for 6 weeks; under 6 years 500- 1000 i.0 twice weekly for 6 weeks; over 6 years 1500 i.0 twice weekly for 6 weeks. If necessary this treatment can be repeated.
In female:
Induction of ovulation & pregnancy: 5000- 10,000 i.0 for one time.
Luteal phase support: 1000-3000 i.u, may be repeated 2 to 3 times, each may be given within 9 days following ovulation or embryo transfer. <br><br><strong>Drug Inter:</strong> No clinically significant drug interactions have been reported during hCG therapy.
Note: For further informatoin, please consult manufacturer's literature.   </p>
          </div><!-- collapsible -->
        
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  PREGNYL Inj. Nuvista </h3>
          <p>  Human chorionic gonadotrophin (HCG), powder for reconstitution, 5000 i.0 ampoule with solvent for i.m injection.
5000 i.0 amp x 3's pack: 3854.91 MRP  </p>
        </div><!-- collapsible -->

        </div><!-- collapsible-set -->



<a href="#" data-role="button"  data-theme="a">  </a>
      <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> OVIDREL 250 Inj. Serono/Janata Healthcare <br>
          (RECOMBINANT CHORIONIC GONADOTROPHIN)  </h3>
          <p>  Ovidrel is a product of choriogonadotrophin alfa produced by recombinant DNA techniques in chinese hamster ovary cells. It shares the amino acid sequence with urinary human chorionic gonadotrophin. This choriogonadotropin has the pharmacological actions of the pituitary luteinizing hormone.
Ovidrel is available as choriogonadotrophin alfa 250mcg powder in vial with solvent for subcutaneous injection. (Each vial contains 285mcg to ensure delivery of 250mcg dose).
A dose of 250mcg is equivalent to approximately 6500 I.U.<br><br>
<strong>Mode of action:</strong> The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum. In women, chorionic gonadotrophin acts as a surrogate LH- surge that triggers ovulation. Chorionic gonadotrophin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/CG receptor, then acts to trigger ovulation.<br><br>
<strong>Ind:</strong> Recombinant chorionic gonadotrophin is indicated in the treatment of :
1. Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Chorionic gonadotrophin is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
2. Anovulatory or oligo-ovulatory women: For induction of ovulation & pregnancy- chorionic gonadotrophin is administered to trigger ovulation and luteinisation in anovulatory or oligo- ovulatory patients after stimulation of follicular growth.
But, there is no clinical experience with recombinant chorionic gonadotrophin in other indications commonly treated with urine derived human chorionic gonadotrophin (hCG).<br><br>
<strong>C/I:</strong> See above under the text of human chorionic gonadotrophin (hCG).
<strong>S/E:</strong> Pre<strong>Cautions:</strong> See above under the text of human chorionic gonadotrophin (hCG), and consult manufacturer's literature.<br><br>
<strong>Dosage & admin:</strong> The following dosing
regimen should be applied:
1. Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): 250mg (1 vial) is administered 24 to 48 hours after the last administration of an FSH- or hMG preparation, i.e when optimal stimulation of follicular growth is achieved.
2. Anovulatory or oligo-ovulatory women:
250mg (1 vial) is administered 24 to 48 hours after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of, and the day after, gonadotrophin injection.
Recombinant chorionic gonadotrophin is intended for subcutaneous administration. The powder should be reconstituted immediately
prior to use with the solvent provided. Treatment with recombinant chorionic gonadotrophin should be performed under the supervision of a physician experienced in the treatment of fertility problems.
Drug & other interactions: No clinically significant drug interactions have been reported during hCG therapy. Following administration, Ovidrel (choriogonadotrophin alfa) may interfere for up to ten days with the immunological determination of serum/urinary hCG, leading to a false positive pregnancy test. During Ovidrel therapy, a minor thyroid stimulation is possible of which the clinical relevance is unknown.
Note: For further informatoin, please consult manufacturer's literature.
250mcg vial x l's pack: 4020.50 MRP  </p>
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->        
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="Drugs for Growth failure" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs for Growth failure   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 



      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>GROWTH HORMONE   </h3>
          <p>  Growth hormone is an anterior pituitary hormone, which has several different functions, but the most physiologic role is to promote protein synthesis and thus helps in the growth of the individual.The deficiency of growth hormone leads to growth failure.
Growth hormone is used in the treatment of growth hormone deficiency (including short stature in Turner syndrome); only the human type is effective since growth hormone is species specific. The use of growth hormone of human origin (somatotrophin) devoloped a fatal neurologic disease (Creutzfeldt-Jakob disease) in several persons. So, it has been replaced by a synthetic growth hormone of human sequence (somatropin), produced by using recombinant DNA technology.  </p>
        </div><!-- collapsible -->
  
      </div><!-- collapsible-set -->




    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  SOMATROPIN  </h3>
          <p>  Somatropin is a biosynthetic human growth hormone (r-hGH) produced by recombinant DNA technology.<br><br>
<strong>Ind:</strong> i) Long term treatment of children who have growth failure due to endogenous growth hormone deficiency; ii) Short stature in Turner syndrome.
Coautions: Only patients with open epiphyses; relative deficiencies of other pituitary hormones (notably hypothyroidism); diabetes mellitus (adjustment of antidiabetic therapy may be necessary); avoid in pregnancy (theoretical risk).<br><br> <strong>S/E:</strong> Antibody formation; local reactions (rotate subcutaneous injection sites to prevent lipo- atrophy); in Turner syndrome temporary exacerbation of lymphoedema reported.<br><br>
<strong>Dosage & admin:</strong> See below under individual products.  </p>
        </div><!-- collapsible -->
      
      <div data-role="collapsible"> <!-- collapsible -->
        <h3>NORDITROPIN Simplex Inj. Novo Nordisk/Transcom</h3>
        <p>  Somatropin 5mg (or 15 units)/1.5ml vial: Subcutaneous injection.<br><br><strong>Ind:</strong> i) Long term treatment of children who have growth failure due to endogenous growth hormone deficiency; ii) Short stature in Turner syndrome.<br><br>
C/I; S/E; Caution: see above<br><br>
<strong>Dosage & admin:</strong> 0.5-0.7 units/kg (Turner syndrome, 1 unit/kg) weekly divided into 6 or 7 doses for subcutaneous injection (may be given by intramuscular injection divided into 2 or 3 doses, but more painful).
Note: Before administration, dissolve the sterile powder in the solvent and prepare a solution for subcutaneous injection.
1.5ml (5mg or 15 units) vial x l's pack: 10500.00 MRP  </p>
      </div><!-- collapsible -->

      </div><!-- collapsible-set -->


    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->


<div data-role="page" id="Drugs for milk suppression" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Drugs for milk suppression  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 


      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>BROMOCRIPTIN MESYLATE Tablet</h3>
          <p>  Preparations: See under the chapter of CNS drugs in the section of 'drugs used in parkinsonism'.  </p>
        </div><!-- collapsible -->
  
      </div><!-- collapsible-set -->


    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="Drugs for menopausal symptoms" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>Drugs for menopausal symptoms: <br>
      Hormone replacement therapy    </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>OESTRADIOL ONLY & <br>
			OESTRADIOL- NORETHISTERONE <br> 
			COMBINED PREPNS</h3>
          <p>Hormonal drugs for replacement therapy (HRT) are prepared in three forms:
1. For 'Oestrogen only HRT'- preparations containing only oestradiol in tablets or patches.
2. For 'Regular period HRT'- preparations containing oestradiol only & oestradiol- norethisterone combinedly in tablets or patches. 3. For 'Period free HRT'- preparations containing oestradiol-norethisterone combinedly in tablets or patches.<br><br>
<strong>Mode of action:</strong> Estradiol is a naturally occuring hormone and norethisterone acetate is a synthetic derivative of 19-nortestosterone. The active hormone of replacement therapy is estradiol, the biologically most potent estrogen produced by the ovary. Its synthesis in the ovarian follicles is regulated by pituitary hormones. Estradiol is secreted at different rates during the menstrual cycle. The endometrium is highly sensitive to estradiol, which regulates endometrial proliferation during the follicular phase of the cycle and together with progesterone, induces secretory changes during the luteal phase. During the menopause estradiol secretion becomes irregular and eventually ceases altogether. The absence of estradiol is associated with menopausal symptoms (such as, vasomotor instability, sleep disturbances, depressive mood, signs of vulvovaginal and urogenital atrophy and with increased bone loss). In addition, there is growing evidence for an increased incidence in cardiovascular disease in the adsence of estrogen. Estrogen replacement therapy has been found effective in most postmenopausal women to compensate for the endogenous estrogen
depletion. However, there is substantial evidence that 'the only estrogen therapy' is associated with an increase in endometrial cancer, but an adjunctive progestogen treatment protects against estrogen-induced endometrial cencer. Therefore, women with an intact uterus should receive combination estrogen-progestogen hormone replacemen therapy.
Norethisterone acetate, a progestogen hormone, when administered prevents estrogen-related endometrial proliferation and thus endometrial cancer.
Indications: Oestradiol only & oestradiol- norethisterone combined preparations are indicated for the treatment of oestrogen deficiency syndrome including prevention of bone mineral content loss as following-
'Oestrogen only HRT'- for hysterectomised women.
'Regular period HRT'- for premenopausal women.
'Period free HRT'- for post menopausal women. Contraindications: Known, suspected, or history of carcioma of the breast. Known or suspected oestrogen dependent neoplasia, e.g endometrial carcinoma. Acute or chronic liver disease, or history of liver disease, where liver function tests have failed to return normal. Deep venous thrombosis, thromboembolic disorders, cerebral vascular accident, or a history of these conditions, associated with previous oestrogen use. Abnormal genital bleeding of unknown aetiology. Known or suspected pregnancy. Porphyria.
Side-effects:
Hormonal drugs for 'regular period HRT': Breast tenderness and bleeding irregularities may occur, specially during the first few months of treatment. Nausea, headache and oedema occur rarely. Symptoms are normally transient. Alopecia, skin reactions and vision abnormalities have been reported. Missed tablets may lead to bleeding episodes. Breast and endometrial cancer, thromboembolic disorders as well as changes in hepatic function have been reported, but there is no reason to believe that the incidence is increased.
Hormonal drugs for 'period free HRT': Main side effects are irregular bleedings which occur most frequently during the first few months of treatment. Women may even bleed from an atrophic endometrium, the reasons for which are presently unknown. After the first month of treatment a gradual decrease in bleeding frequency is normally seen. Bleedings may continue in some postmenopausal women; in these cases consideration should be given to change to an alternative therapy. Missed tablets may lead to bleeding episodes. Breast tenderness, nausea, headache and oedema may occur. Symptoms are normally transient. Alopecia, skin reactions and vision abnormalities have been reported. Breast cancer and thromboembolic disorders have been reported, but there is no reason to believe that incidence is increased. 'Oestrogen (oestradiol) only HRT': During the first few months of treatment breast tenderness may occur. Nausea, headache and oedema may occur rarely. Symptoms are normally transient. Skin reactions have been reported. Missed tablets may lead to bleeding in women with an intact uterus.
Warnings: Treatment with unopposed oestrogens is known to increase the risk of endometrial cancer. The risk appears to depend on both duration of treatment and on oestrogen dose. Endometrial hyerplasia (atypical or adenomatous) often precedes endometrial cancer. Recent prospective studies suggest that an excess of endometrial hyperplasia can virtually be avoided if the endometrium is protected by a sufficient dose of progestogen for at least 10 days. Kliogest- recent studies show that an excess of endometrial hyperplasia can virtually be avoided since the endometrium is brought to an atrophic state by continuous administration of progestogen during the entire oestrogen treatment period. Long term use of oestrogen replacement therapy in high doses is associated with an increase in breast cancer risk. Use of small doses for short periods shows no measurable increase in risk. The effects of smaller doses of oestrogen for long
periods are not adequately studied, but are not likely to be associated with any substantially increased risk of breast cancer.<br><br>
Pre<strong>Cautions:</strong> A physical examination and complete medical and family history should be taken prior to initiation of oestrogen therapy, especially- blood pressure, breast and abdominal examination, and a gynaecological examination. Women with an intact uterus who are or have previously been treated with unopposed oestrogens, should be examined with special care to investigate possible hyperstimulation of the endometrium before starting therapy. In general, oestrogen should not be prescribed for longer than one year without performing another physical and gynaecological examination. And the lowest dose of HRT which alleviates symptoms should be prescribed. Women in antihypertensive treatment or women with epilepsy, migraine, diabetes, asthma or cardiac failure should be monitored regularly. Thromboembolism has been reported in connection with oestrogen replacement therapy, but there is no background to believe the overall incidence is increased.
These preparations have no contraceptive effects.
Oestrogen only HRT / Regular period HRT:
If abnormal or irregular bleedings occur during or shortly after therapy, diagnostic aspiration biopsy or curettage should be performed to rule out possibility of uterine malignancy.
Period free HRT: During the first few months bleedings or spottings may occur, but are usually transient and do not require diagnostic aspiration biopsy or curettage; however, if bleedings or spottings continue or first appear at a later stage in treatment or shortly after therapy has been stopped, diagnostic aspiration biopsy or curettage should be performed to rule out possibility of uterine malignancy.
Period free HRT / Regular period HRT:
Long term prophylactic treatment of osteoporosis should be restriceted to women at increased risk of developing fractures. Factors predisposing to osteoporosis- White/Asian race, female sex, thin or petite, family history of the disease, pre- or postmenopausal oestrogen deficiency, early menopause, inadequate calcium nutrition, cigratte smoking, alcohol abuse, sedentary life-style. Indications for immediate withdrawal of therapy: Deep venous thrombosis, thromboembolic disorders, appearance of jaundice, emergence of migraine-type headache, sudden visual disturbances, significant increase in blood pressure. Withdrawal of treatment 4-6 weeks prior to major surgery is advised.</p>
        </div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
            <h3>ESTRIMAX Tab. Gedeon Richter/City Overseas</h3>
            <p>Triaklim tablets are prepared for 'regular period HRT' for premenopausal women; 28 tablets pack- 12 blue tablets each containing 2mg oestradiol, 10 white tablets each containing 2mg oestradiol and 1mg norethisterone acetate, 6 red tablets each containing 1mg oestradiol.
Pausogest tablets are prepared for 'period free HRT' for postmenopausal women; 28 tablets pack, each tablet containing 2mg oestradiol and 1mg norethisterone acetate.
Estrimax tablets are prepared for 'oestrogen only HRT' for hysterectomised women; 28 tablets pack, each tablet containing 2mg oestradiol. Indications: Triaklim, Pausogest and Estrimax are indicated for the treatment of oestrogen deficiency syndrome including prevention of bone mineral content loss.
Triaklim - for premenopausal women. Pausogest - for post menopausal women. Estrimax - for hysterectomised women.<br><br> C/I; S/E; Warnings; Precautins: See above under the text of HRT.
<strong>Dosage & admin:</strong> Oral administration, one tablet daily without interruption.
Estrimax: Treatment of hysterectomized or post-menopausal women may start on any day; if patient is menstruating, start on day 5 of bleeding. Initiate treatment with Estrimax; if clinical response is unsatisfactory, Estrimax forte may be tried. Replace Estrimax forte with Estrimax as soon as symptoms can be relieved with a lower dose.
Triaklim: Regular withdrawal bleeding will be established, usually during administration of the low oestrogen tablets, i.e the 6 red tablets, or even during last phase of white tablets. In menstruating women or women already on HRT, treatment should start on day 5 of bleeding, other women on any day. Initiate â¢ treatment with Triaklim; if clinical response is unsatisfactory, Triaklim forte may be tried. Replace Triaklim forte with Triaklim as soon as symptoms can be relieved with lower dose. Pausogest: Treatment with Pausogest should preferably not be initiate earlier than one year after menopause. Treatment may start on any day.
Indications for immediate withdrawal of therapy:
See above under the text of HRT.
Note: For further information, please consult
manufacturer's literature.
Triaklim 28 tabs pack: 450.24 TP Pausogest 28 tabs pack: 683.13 TP Estrimax 28 tabs pack: 403.67 TP</p>   
        </div><!-- collapsible -->


      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> TIBOLONE  </h3>
          <p>  Tibolone is a synthetic steroid with tissue specific
estrogenic, progestogenic and androgenic effect. It is recently introduced for the 'hormone replacement therapy (HRT)' of the menopausal symptoms & other associated post-menopausal conditions.<br><br>
<strong>Mode of action:</strong> As tibolone has got a combined oestrogenic and progestogenic activity with weak androgenic activity; it suppesses the gonadotrophin levels in postmenopausal women (and inhibits ovulation in fertile women). Following oral administration tibolone is rapidly metabolized into three compounds, which contribute to the pharmacological effects of tibolone. Two of these metabolites (3 alpha- hydroxide-tibolone and 3 beta-hydroxide-tibolone) have predominantly estrogenic activity, a third metabolite (delta 4-isomer of tibolone) and the parent compound have progestogenic and androgenic activities.
It is given continuously without cyclical
progestogen.<br><br>
<strong>Ind:</strong> 1. Treatment of the climacteric symptoms (or vasomotor symptoms, such as- hot flushes, sweating, vaginal dryness & less elasticity, mood disorders, anxiety etc.)following natural or surgical menopause, (unsuitable for use within 12 months of the last menstrual period- may cause irregular bleeding).
2. Prevention of post-menopausal and post- oophorectomy osteoporosis and improvement of bone-mineral density in patients with established post-menopausal osteoporosis.
3. Vaginal atrophy.
4. Prevention of frequent UTI and urinary incontinence in post-menopausal women.<br><br>
<strong>C/I:</strong> Pregnancy & breast-feeding; hormone- dependent tumours; history of cardiovascular or cerebrovascular disease; vaginal bleeding of unknown etiology; severe liver disorders.<br><br>
<strong>S/E:</strong> Occasionaly weight changes, pretibial oedema, dizziness, seborrhoeic dermatosis, vaginal bleeding, headache, gastro-intestinal disturbances, increased facial hair, migraine, visual disturbances, chnange in liver function tests, rash and pruritus.<br><br>
<strong>Cautions:</strong> Renal inpairment, epilepsy, migraine, diabetes mellitus, hypercholesterolaemia; withdraw if signs of thrombo-embolic disease, abnormal liver function tests or cholestatic jaundice.
Warnings: To avoid irregular & abnormal bleeding, tibolone should be started at least 12 months after last natural bleeding.
A higer dose than the recommended one may induce vaginal bleeding; when higher doses are used, additional administration of progestogen at regular intervals is advisable, for instance every 3 months for 10 days.
If changing from another preparation for hormone replacement therapy, the endometrium may already be stimulated, so induction of a withdrawal bleed with a progestogen is advisable. During prolonged treatment with steroids with hormonal activity, periodic medical examination is advisable.
Tibolone is not intended for contraceptive use. <br><br><strong>Dosage & admin:</strong> Climacteric or vasomotor symptoms following natural or surgical menopause, & other post-menopausal problems: 2.5mg daily preferably at the same time. Improvement of symptoms generally occurs within a few weeks, but optimal results are obtanined when therapy is continued for at least 3 months. At this recommended dosage, it may be used uninterruptedly for longer periods. To prevent osteoporosis in post- menopausal women or after oophorectomy an uninterrupted long-term (5-10 years) therapy, at a rate of 2.5mg/day is needed.
In case of missed pill, if no more than 12 hours have passed, the pill should be taken immediately, otherwise the next dose should be continued as before.<br><br>
<strong>Drug Inter:</strong> Since tibolone may increase blood fibrinolytic activity, it may enhance the effect of anticoagulants. This effect has been reported with warfarin. Drugs that induce hepatic microsomal enzymes or other enzyme inducing drugs may accelerate the metabolism of tibolone and thus lower its activity.  </p>
        </div><!-- collapsible -->
      
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>LIVIAL Tab. Nuvista</h3>
            <p>Tibolone 2.5mg/tablet. 28's pack: 1172.50 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MENOREST Tab. Renata</h3>
            <p>Tibolone 2.5mg/tablet. 30's pack: 600.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TIBONE Tab. Techno Drugs</h3>
            <p>Tibolone 2.5mg/tablet. 30's pack: 450.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>UBILON Tab. Incepta</h3>
            <p>Tibolone INN 2.5mg/tablet. 30's pack: 600.00 MRP</p>   
        </div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->


<div data-role="page" id="Hormone prepns. for other uses" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Hormone prepns. for other uses  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  SOIVIATOSTATIN </h3>
          <p>SOMATOSTATIN: Injection for i.v infusion Somatostatin a synthetic peptide hormone, available as injection for intravenous infusion. <br><br><strong>Ind:</strong> Severe acute haemorrhage from gastric & duodenal ulcer; bleeding from acute erosive & haemorrhagic gastritis, oesophageal varices; pancreatic, biliary & g.i fistulae, complications of postoperative pancreatitis; acute pancreatitis. <br><br><strong>C/I:</strong> Pregnancy, puerperium & lactation period. <br><br><strong>S/E:</strong> Nausea, flushing, g.i distress, diarrh oea & minor fluctuations in blood sugar.
          <strong>Dosage & admin:</strong> Administer at a rate of 250mcg/hour or 6mg (2 maps) in 24 hours in a continuous infusion until documented cessation of bleeidng for upto even 5 days.
          Duration of infusion: for bleeding, 5-120 hours; prophylaxis, 120-140 hours; fistulae, 5-15 days. Reports of continuous infusion upto 37 days without complications are available.</p>
        </div><!-- collapsible -->
  
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  STILAMIN Inj. Serono/Janata </h3>
          <p>  Somatostatin (a synthetic peptide hormone) 250mcg & 3mg ampoule: Injection. 250mcg amp: 1311.76 MRP
          3mg amp: 5892.90 MRP  </p>
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->


<div data-role="page" id="OTHER ENDOCRINE DRUGS" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs affecting (inhibiting) gonadotrophins   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CETRORELIX  </h3>
          <p>  Cetrorelix acetate 0.26-0.27mg equivalent to cetrorelix 0.25mg/vial: powder for injection with one pre-filled syringe containing 1ml water as solvent.<br><br>
<strong>Mode of action:</strong> Cetrorelix inhibits the effects of a natural hormone, called luteinising hormone releasing hormone (LHRH). LHRH regulates the secretion of luteinising hormone (LH), which induces ovulation during the menstrual cycle. Cetrorelix inhibits premature ovulation which is undesirable during hormone treatment for ovarian stimulation as only mature egg cells are suitable for fertilisation.<br><br>
<strong>Ind:</strong> Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.<br><br>
<strong>C/I:</strong> Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol; pregnancy and lactation; postmenopausal women; patients with moderate and severe renal and hepatic impairment.<br><br>
<strong>S/E:</strong> Mild and transient reactions at the injection site, e.g erythema, itching and swelling. Occasionally systemic side effects, e.g nausea and headache have been reported. In addition, a single case of pruritus has been reported during treatment with cetrorelix.
A severe hypersensitivity reaction, associated with cough, rash and hypotension, was observed in one patient after 7 months of treatment of ovarian cancer with cetrorelix (10mg/day). The patient recovered completely within 20 minutes. A causal relationship could not be excluded.
Occasionally an ovarian hyperstimulation syndrome (OHSS) can occur which is an intrinsic risk of the stimulation procedure (see precautions & warnings for use). Symptoms like abdominal pain, tension, nausea, vomiting, diarrhoea and breathing difficulties may indicate an OHSS. Please inform the concerned doctor immediately, if the patient feels such symptoms.
If the patient notices any unwanted effect not mentioned in the list of side-effects or if she is unsure about the effect of this medicine, please inform the concerned doctor immediately. Precautions & warnings: During or
following ovarian stimulation an ovarian
hyperstimulation syndrome can occur. This event must be considered as an intrinsic risk of the stimulation procedure with gonadotropins.
An ovarian hyperstimulation syndrome should be treated symptomatically, e.g with rest, intravenous electrolytes/colloids and heparin therapy. Luteal phase support should be given according to the reproductive medical centre's practice.
There is limited experience up to now with the administration of cetrorelix during a repeated ovarian stimulation procedure. Therefore, cetrorelix should be used in repeated cycles only after a careful risk/benefit evaluation. <br><br><strong>Pregnancy & lactation:</strong> Cetrorelix is not inteneded to be used during pregnancy and lactation. Studies in animals have indicated that cetrorelix exerts dose related influence on fertility, reproductive performance and pregnancy. No teratogenic effects occured when the drug was administered during the sensitive phase of gestation.<br><br>
<strong>Dosage & admin:</strong> Cetrorelix 0.25mg should only be prescribed by a specialist experienced in this field.
Cetrorelix 0.25mg is for subcutaneous injection into the lower abdominal wall.
The content of 1 vial (0.25mg cetrorelix) is to be administered once daily, at 24 hours intervals, either in the morning or in the evening.
Administration in the morning: Treatment with cetrorelix 0.25mg in the morning should commence on day 5 or 6 of ovarian stimulation (approximately 96 to 120 hours after start of ovarian stimulation) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period including the day of ovulation induction.
Administration in the evening: Theratment with cetrorelix 0.25mg in the evening should commence on day 5 of ovarian stimulation (approximately 96 to 108 hours after start of ovarian stimulation) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period until the evening prior to the day of ovulation induction.
Cetrorelix injection can be administered by the patient herself after appropriate instructions by her doctor. (For instructions for use and handling the injection- see manufacturer's literature).
Missing a dose: Ideally cetrorelix 0.25mg should be administered at 24 hours intervals. But if missed to administer the injection at the right time it is no problem to administer this dose at a different time of the smae day. If missed to administer cetrorelix 0.25mg on one day, please contact the concerned doctor immediately and ask for advice.<br><br>
<strong>Drug Inter:</strong> In vitro investigations have shown that interactions are unlikely with medications that are metabolised by cytochrome P450 or glucuronised or conjugated in some other way. However, the possibility of interactions with commonly used medicinal products cannot entirely be excluded.
0.25mg vial with water in pre-filled syringe x 7's pack: 17852.24 MRP  </p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->
   
   <div data-role="collapsible-set" data-theme="b">

     <div data-role="collapsible"> <!-- collapsible -->
       <h3> DANAZOL  </h3>
       <p> Danazol is a synthetic steroid drug derived from ethisterone.
Different studies established that the drug is neither oestrogenic nor progestational but has some weak androgenic activity, which is dose related. Danazol inhibits pituitary gonadotrophins i.e it depresses the output of both follicle- stimulating hormone (FSH) and luteinizing hormone (LH).<br><br>
<strong>Ind:</strong> Endometriosis; benign (fibrocystic) breast cysts; gynaecomastia; menorrha-gia; severe cyclical mastalgia; pre-operative thining of endometrium; hereditary angioedema (of all types).<br><br>
<strong>C/I:</strong> Pregnancy; breast-feeding; undiagnosed abnormal genital bleeding; markedly impaired hepatic, renal or cardiac function; thromboembolic diseases; androgen-dependent tumours; porphyria.<br><br>
<strong>S/E:</strong> nausea, dizziness, skin reactions including rashes, photosensitivity and exfoliative dermatitis, fever, backache, nervousness, mood changes, anxiety, changes in libido, vertigo, fatigue, epigastric and pleuritic pain, headache, weight gain; menstrual disturbances, vaginal dryness and irritation, flushing and reduction in breast size; musculo-skeletal spasm, joint pain and swelling, hair loss; androgenic effects including acne, oily skin, oedema, hirsutism, voice changes and rarely clitoral hypertrophy; temporary alteration in lipoproteins and other metabolic changes, insulin resistance; thrombotic events; leucopenia, thrombocytopenia, eosinophilia, reversi-ble erythrocytosis or polycythaemia reported; headache and visual disturb-ances may indicate benign intracranial hypertension; rarely cholestatic jaundice, pancreatitis, peliosis hepatis and benign hepatic adenomata.
<br><br><strong>Cautions:</strong> Because danazol may cause some degree of fluid retention, conditions that might be influenced by this factor, such as epilepsy, migraine, cardiac or renal function, hypertension require careful observation. Elderly. Withdraw treatment if virilisation.
Warnings: As danazol is contra-indicated in pregnancy, a pregnancy test is recommended prior to starting therapy. Additionally a non-hormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, therapy should be discontinued and the patient should be apprised of the potential risk of the foetus.
<br><br><strong>Dosage & admin:</strong> Drug treatment usually given in up to 4 divided doses; in women of child- bearing potential, treatment should start during menstruation, preferably on day 1. Endometriosis: 200-800mg daily in up to 4 divided doses, adjusted to achieve maenorrhoea, usually for 6 months (up to 9 months in some cases).
Menorrhagia: 200mg daily, usually for 3 months (but in view of its side-effects, treatment with other drugs may be preferable). Severe cyclical mastalgia: 100-400mg daily usually for 3-6 months.
Benign breast cysts: 300mg daily usually for 3-6 months.Gynaecomastia: 400mg daily in up to 4 divided doses for 6 months (adolescents 200mg daily, increased to 400mg daily if no response after 2 months).
Pre-operative thinning of endometrium: 400- 800mg daily in up to 4 divided doses for 3-6 weeks.
Hereditary angioedema: Start with 200mg 2 or 3 times daily. After favourable initial respone (is obtained in terms of prevention of episodes
of oedematous attacks) the proper continuing dosage should be determined by decreasing the dosage by 50% or less at intervals of 1-3 months or longer if frequency of attacks prior to treatment dictates. If an attack occurs during therapy the daily dosage may be increased by up to 200mg.   </p>
     </div><!-- collapsible -->
   
   <div data-role="collapsible"> <!-- collapsible -->
   <h3>ANARGIL Cap. Medochemie/ Hyeimpex</h3> 
   <p>Danazol 200mg/capsule.
   200mg x 100's pack: 3876.42 MRP</p>
   </div><!-- collapsible -->


   <div data-role="collapsible"> <!-- collapsible -->
    <h3>DANAMET Cap. SK+F </h3>
    <p>Danazol 100mg & 200mg/capsule. 100mg x 18's pack: 324.00 MRP 200mg x 18's pack: 630.00 MRP</p>
   </div><!-- collapsible -->


   <div data-role="collapsible"> <!-- collapsible -->
   <h3>LOZANA Cap. Incepta</h3> 
   <p>Danazol 100mg & 200mg/capsule. 100mg x 20's pack: 400.00 MRP 200mg x 14's pack: 532.00 MRP
   </p>
   </div><!-- collapsible -->

   </div><!-- collapsible-set -->
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

</body> 
</html> 
